



CURRICULUM VITAE

Elizabeth J. Shpall, MD

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Ashbel Smith Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008–2013

Medical Director, Cell Therapy Laboratory, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

Director, Cord Blood Bank, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

Deputy Department Chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

HOME ADDRESS

2001 Holcombe Blvd. Unit 1901
Houston, TX 77030
Phone: 281-501-8702

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
Stem Cell and Transplantation & Cellular Therapy
1515 Holcombe Boulevard
Unit Number: 423
Houston, TX 77030
Room Number: FC5.3050
Phone: 713-745-2161
Fax: 713-794-4902
Email: eshpall@mdanderson.org

EDUCATION

Degree-Granting Education

Brown University, Providence, RI, BA Equivalent, 1976, Biology and French

University of Cincinnati College of Medicine, Cincinnati, OH, MD, 1980, Medicine

Postgraduate Training

Clinical Residency, Beth Israel Hospital, New York, NY, 1/1980–6/1983

Clinical Fellowship, Mount Sinai Medical Center, New York, NY, 1/1984–6/1985

CREDENTIALS

Board Certification

American Board of Internal Medicine, 90612, 1/1983

American Board of Medical Oncology, 90612, 1/1987

Licensures

Active

TX, #L5561, 1/2002–8/2007

Inactive

NY, #147886, 1/1981–1/1986

NC, #30485, 1/1986–1/1991

CO, #31034, 1/1990–1/2003

EXPERIENCE/SERVICE

Academic Appointments

Instructor, Mount Sinai Medical Center, New York, NY, 1/1985–1/1986

Assistant Professor, Duke University Medical Center, Durham, NC, 1/1986–1/1990

Associate Professor, Department of Internal Medicine, University of Colorado Health Sciences Center, Denver, CO, 1/1990–1/1996

Professor, Department of Internal Medicine, University of Colorado Health Sciences Center, Denver, CO, 1/1996–1/2002

Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2002–present

Administrative Appointments/Responsibilities

Director, Cryopreservation Laboratory, Duke University Medical Center, Durham, NC, 1/1988–1/1990

Associate Director, Bone Marrow Transplant Program, University of Colorado Health Sciences Center, Denver, CO, 1/1990–1/2002

Director, Stem Cell Engineering Laboratories and Apheresis Unit, University of Colorado Health Sciences Center, Denver, CO, 1/1990–1/2002

Director, Cord Blood Bank, The University of Colorado, Denver, CO, 1/1997–1/2002

Medical Director, Cell Therapy Laboratory, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 1/2002–present

Director, Cord Blood Bank, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 1/2004–present

Deputy Department Chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2010–present

Other Appointments/Responsibilities

Member, The Abraham J. and Phyllis Katz Cord Blood Foundation, Cleveland, OH, 10/2008–present

Member, HHS Advisory Council on Blood, Washington, DC, 5/2011

Member, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) State of the Science Symposium (SOSS), Milwaukee, WI, 7/2011–7/2017

Member, BMT CTN SOSS Donor & Graft Source Committee, Houston, TX, 7/2011–7/2017

Chair, ISCT 2013 Abstract Review Committee, Houston, TX, 12/2012–1/2013

Member, Scholarship Oversight Committee (SOC), Houston, TX, 12/2012–12/2013

Endowed Positions

Ashbel Smith Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008–2013

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

Search Committee, Chairman Department of Emergency Medicine, Member, 1/2003–1/2004

Search Committee, Chairman Department General Internal medicine, Member, 1/2003–12/2004

GMP Cell Therapy Laboratory Steering Committee, Member, 8/2003–present

Faculty Senate, Member, 1/2004–1/2007

Cord Blood Bank Steering Committee, Chairman, 12/2004–present

Tissue Transplantation Committee, Member, 1/2007–1/2008

Cancer Center Support Grant- Immunology Program, Member, 1/2007–present

American Society of Clinical Oncology Young Investigators Award Oversight Committee, Member, 7/2008–7/2009

Institutional Review Board (IRB) #1, Member, 9/2008–9/2009

Third Annual DoCM Faculty Recognition and Award Program Nomination Reviews, Member, 11/2008–12/2008

Department of Stem Cell Transplantation and Cellular Therapy, Ongoing Professional Practice Evaluation (OPPE) Committee, Quality Officer and Member, 3/2009–3/2012

Women Faculty Programs Departmental Liaison, Member, 2/2010–present

The Multidisciplinary Research Advisory Committee (MRAC), Member, 3/2010–3/2011

Promotion and Tenure Committee, Member, 9/2010–present

Embryonic Stem Cell Research Oversight Committee, Member, 4/2011–present

Search Committee Department of Gynecologic Oncology and Reproductive Medicine, Chairman, 11/2011–8/2012

Professional Liability Committee (PLC), Member, 6/2012–present

Clinical Research Committee (CRC) #2, Chairman, 10/2012–present

Steering Committee for the Society of Hematologic Oncology (SOHO), Member, 11/2013–present

HONORS AND AWARDS

American Board of Internal Medicine, 1983

ACS Institutional Research Grant Award, Institutional Research Grant Award, 1987

American Board of Medical Oncology, 1987

ACS Career Development Award, 1989

Best Doctor in America, America's Top Doctor, 2001–present

Clinical Physician, Texas Federation of Business and Professional Women's Club (BPW), 2007–2008

Ashbel Smith Professor, MD Anderson Cancer Center, 2008–2013

The Irwin H. Krakoff Award for Excellence in Clinical Research, MD Anderson Cancer Center, 2009–2010

The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research, MD Anderson Cancer Center, 2010–2011

President's Recognition for Faculty Excellence Award, MD Anderson Cancer Center, 2014–present

RESEARCH

Grants and Contracts (past 5 years)

Funded

Principal Investigator, 12%, Hematopoietic Progenitor Cell- Cord Blood, R01CA061508-17, NIH/NCI, 9/17/1993–1/31/2015, \$1,533,842 (\$287,596/year)

Core Leader, 15%, Therapy of Chronic Myelogenous Leukemia (CML)- Core E, P01CA49696-19, NIH/NCI, PI - Richard Champlin, 2/12/1997–6/30/2015 (\$312,587/year)

Co-Investigator, 1%, NIH SPORE in Ovarian Cancer, 1P50 CA83639, NIH/NCI, PI - Robert Bast, 10/1/1999–9/30/2015 (\$194,000/year)

Principal Investigator, 1%, Cord Blood Expansion on Mesenchymal Stem Cells, CS2006-00015733, Viacell, 6/20/2006–6/20/2015, \$212,120 (\$35,353/year)

Principal Investigator, 1%, Cord Blood Bank Protocol, HSHH234200737001C, Department of Health and Human Services, Health Resources and Services Administration , 11/2/2006–11/1/2016, \$9,729,919 (\$3,243,306/year)

Co-Investigator, 2%, Imaging T cells by positron emission tomography, 1R01CA163587-01, NIH/NCI, PI - Laurence Cooper, 8/20/2007–5/31/2014, \$3,014,738 (\$602,947/year)

Co-Investigator, 0.12 months, Activation & Expansion of CLL specific T-cells to study the immune reconstitution following Infusion of CD3/CD28 bead- activated and expanded T cells in patients with chronic lymphocytic leukemia following alemtuzumab based therapy, CLL Global Research Foundation, PI - Hosing, 2/26/2008–5/31/2014 (\$160,000/year)

Principal Investigator, 10%, Improving Cord Blood Expansion and Homing for Patients with Cancer, RP100469-01, Cancer Prevention & Research Institute of Texas (CPRIT), 8/1/2010–1/31/2014, NCE, \$921,654 (\$307,218/year)

Principal Investigator, 1%, Cord Blood Bank Protocol, HSHH250201000011C, Department of Health and Human Services, Health Resources and Services Administration , 8/30/2010–8/29/2014, \$12,697,688 (\$2,706,853/year)

Co-Investigator, 2%, SPORE in Human Cancers for the Years 2008 and 2009 (PP-1), P50 CA142509, NIH/NCI, PI - Larry Kwak, 9/22/2010–8/31/2015, \$1,608,314 (\$145,000/year)

Co-Investigator, 5%, Adoptive Immunotherapy With NK Cells Expanded Ex Vivo For Treatment of Hematopoietic Malignancies, RP110553-P3, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Champlin, 7/1/2011–6/30/2016, \$1,625,602 (\$309,330/year)

Principal Investigator, 10%, MIRA-Cellular Therapy for Cancer GMP Core 2, RP110619 (RP110553C2), Cancer Prevention & Research Institute of Texas (CPRIT), 7/1/2011–6/30/2016, \$996,857 (\$199,371/year)

Principal Investigator, 20%, Improving Cord Blood Transplantation, 1 P01 CA148600-01, NIH/NCI, 9/22/2011–8/31/2016, \$1,250,640 (\$1,915,090/year)

Core Leader, 5%, Improving Cord Blood Transplantation (Core A), 1 P01 CA148600-01, NIH/NCI, PI - Elizabeth Shpall, 9/22/2011–8/31/2016, \$521,362 (\$33,376/year)

Core Leader, 5%, Improving Cord Blood Transplantation (Core C), 1 P01 CA148600-01, NIH/NCI, PI - Elizabeth Shpall, 9/22/2011–8/31/2016, \$2,510,135 (\$157,098/year)

Project Leader, 15%, Improving Cord Blood Transplantation (PP-1), 1 P01 CA148600-01, NIH/NCI, 9/22/2011–8/31/2016, \$2,486,068 (\$243,067/year)

Co-Investigator, 10%, CD19-Specific T-Cell Therapy after Cord Blood Transplantation, 1439, Food and Drug Administration (FDA), PI - Cooper, 11/2/2012–10/31/2015 (\$200,000/year)

Principal Investigator, 1%, Activation and expansion of NK cells in chronic lymphocytic leukemia (CLL) for adoptive therapy, 12114776, CLL Global Research Foundation, 12/1/2012–11/30/2014, \$500,000 (\$250,000/year)

Principal Investigator-MDACC, 1%, Correlating TCR diversity to immune reconstitution after cord blood transplant, 12114775, NHLBI Fred Hutchison Cancer Center, 4/1/2013–3/31/2015, \$22,200 (\$11,100/year)

Principal Investigator, 1%, Cord Blood Cells Ex Vivo Expanded with MPCs (Clinical Supply), 00000783, Mesoblast, Inc., 5/1/2013–1/30/2018, \$1,443,874 (\$721,937/year)

Principal Investigator, 1%, Cord Blood Cells Ex Vivo Expanded with MPC's (Clinical), 00000572, Mesoblast, Inc, 5/1/2013–1/30/2018, \$875,752 (\$218,938/year)

Project Leader, 0.12 months, Project 3: Target GD2+ BCSCs using T-cells expressing GD2-specific chimeric antigen receptors (CARs), Institutional Support, Multidisciplinary Research, PI - Andreeff, 7/1/2013–6/30/2016, \$62,500 (\$25,000/year)

Principal Investigator, 1%, NiCord® Sickle Cell Pilot Study, Gamida Cell Ltd., 8/1/2013–7/31/2017, \$209,538 (\$52,385/year)

Co-Investigator, 1%, Curative cell-based therapies for chronic lymphocytic leukemia (CLL), Sister Institution Network Fund Grant, 12/1/2013–11/30/2015, \$100,000 (\$50,000/year)

Pending

Co-Investigator, 1%, Targeting Notch in CLL, 12104513, NIH/NCI, PI - Patrick Zweidler-McKay, 4/1/2013–3/31/2015, \$275,000 (\$137,500/year)

Co-Investigator, 0.12 months, CLL Moonshot Flagship Project, Moonshot, PI - Shpall, 9/1/2013–8/31/2014, \$432,800

Co-Investigator, 1%, Mobilization of MSCs in Normal Allogeneic Donors, 13076334, Leukemia and Lymphoma Society, PI - Ian McNiece, 10/1/2013–9/30/2016, \$180,018 (\$540,054/year)

Co-Investigator, 0.12 months, All-in-One Purification and Engineering of Therapeutic Cell Systems scored #1 in study section so likely funded 2/2014, 1R21EB017384-01A1, NIH/NCI, PI - Lapotko, 4/1/2014–3/31/2016 (\$50,000/year)

Co-Investigator, 1%, ASC-101-treated MSCs in GVHD, 10636, Small Business Innovation Research Grant, PI - McNiece, 7/1/2014–6/30/2015 (\$94,937/year)

Collaborator, 1%, Investigation of ex vivo fucosylation to enhance the efficacy of adoptive T cell immunotherapy, RP140562, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Al-Atrash, 8/21/2014–8/30/2017, \$275,396 (\$826,189/year)

Other

N/A

Completed

Project Leader, Specialized Center for Cell Based Therapy, U54#HL081030-01, NIH, 8/31/2005–9/1/2010, \$789,769,000

Co-Investigator, 4%, UTMDACC SPORE in Breast Cancer (PP-3), 5P50CA116199-05, NIH/NCI, PI - Gabriel Hortobagyi, 9/23/2005–8/31/2011, \$879,875 (\$146,645/year)

Principal Investigator, 0.12 months, Cord Blood Banking, Cockrell Foundation, 1/1/2006–12/31/2010 (\$125,000/year)

Principal Investigator, 1%, Expansion of hematopoietic progenitor cells for transplantation in patients with hematologic malignancies., 1260603, The Katz Foundation, 8/1/2006–8/31/2010 (\$200,000/year)

Co-Investigator, Cardiovascular Cell Therapy Research Network , HL087365-01, NHLBI, PI - James Willerson, 1/1/2007–12/31/2011, \$1,998,764

Co-Investigator, 1%, Enhancing the efficacy of CD19-Specific Cord Blood-Derived T Cells, R01CA120956, NIH/NCI, PI - Cooper, 2/5/2007–12/31/2011, \$1,250,000 (\$250,000/year)

Principal Investigator, 1%, Cord blood expansion with a copper chelator and a primitive cytokine regimen, CS2006-00018273AB, Gamida Cell, 3/9/2007–1/31/2012, \$422,500 (\$46,944/year)

Principal Investigator, Ex Vivo Expansion to Improve Survival following cord Blood Transplantation, HL087365, Gillson-Longenbaugh Foundation, 7/16/2007–8/31/2009, \$25,000

Principal Investigator, Ex Vivo Expansion to Improve Survival following cord Blood Transplantation, Carl C. Anderson Sr. & Marie Jo Anderson Charitable Foundation, 8/1/2007–8/31/2009, \$25,000

Co-Investigator, 5%, Adoptive Immunotherapy After Umbilical Cord Blood Transplant, 5R01CA124782-05, NIH/NCI, PI - Laurence Cooper, 8/20/2007–5/31/2013, \$944,300 (\$188,860/year)

Core D Leader, 5%, Translational Development of Novel Vaccine Therapies, 7262-08-04-06-061-32, Leukemia and Lymphoma Society, PI - Larry Kwak, 10/1/2007–9/30/2012, \$1,250,000 (\$1,250,000/year)

Co-Investigator, 1.5%, Activation and Expansion of Chronic lymphocytic leukemia (CLL) specific T-cells, CS2007-00021455RG, CLL Global Research Foundation, PI - Hosing, 5/29/2008–6/30/2011, \$400,000 (\$133,333/year)

Principal Investigator, 1%, Cord Blood Expansion on Mesenchymal Stem Cells, CS2008-00023693JW, Angioblast Systems Inc, 8/29/2008–8/31/2012, \$670,533 (\$74,504/year)

Co-Investigator, 1%, Extracorporeal Thermo-ablation of Circulating Cancer Cells/Stem Cells Using Targe, IR43 CA 132420-01, NIH/NCI, PI - Coleman, 12/1/2008–11/30/2010, \$321,490 (\$48,932/year)

Co-Investigator, 1%, Immune reconstitution after cord blood transplantation, 5R01HL091749-04, NIH/NHLBI, PI - Komanduri, 4/1/2009–12/31/2012, \$308,000 (\$77,000/year)

Principal Investigator, 1%, Cord Blood Collection for Translational Research, LS2009-00027280EB, American Stem Cell, Inc. (ASC), 7/1/2009–6/30/2011, \$193,959 (\$64,653/year)

Principal Investigator, 1%, Improving Survival of Cord Blood Transplant Patients, Baylor College of Medicine-MD Anderson Multi-Institutional Research Project, U54HL081007-05, BCM-MDACC MRP, 9/1/2009–8/31/2011, \$196,200 (\$78,480/year)

Principal Investigator, 1%, Ex vivo Expansion of Cord Blood Natural Killer cells for CLL Therapy, LAB02-630, CLL Global Research Foundation, 2/10/2010–6/30/2011, \$47,619 (\$47,619/year)

Principal Investigator, 1%, Cord Blood Banking, 19146, National Marrow Donor Program, 4/1/2010–2/28/2012, \$123,006 (\$123,006/year)

Principal Investigator, 1%, Validation of Stem Cell Potency Assays , 19146 01, NMDP Collaborative Agreement, 4/1/2010–2/28/2012, \$161,000 (\$80,500/year)

Principal Investigator, 5%, Cord Blood Natural Killer Cells for Patients with Cancer, HIRP100430-01, Cancer Prevention & Research Institute of Texas (CPRIT), 5/1/2010–4/30/2013, \$190,238 (\$95,119/year)

Not Funded

N/A

Protocols

Funded

Co-Principal Investigator, A Study to collect peripheral blood samples from donors and recipients of blood and marrow transplants for laboratory research immune reconstitution, LAB00-099, PI - Komanduri, 2000–present, NHLBI-R21

Principal Investigator, Collection and Cryopreservation of Peripheral Blood, Bone Marrow or Apheresis Cells for Cellular Therapies, LAB02-630, 2002–present, \$200,040, KATZ Foundation

Co-Principal Investigator, The Ex Vivo Expansion of Allogeneic Cord Blood Progenitors for Patients with Hematologic Malignancies, ID02-407, PI - de Lima, Marcos, 2002–present, RO1

Co-Principal Investigator, Cord Blood Ex-Vivo Expansion, ID02-455, 2003–2006, NCI

Principal Investigator, Cord Blood Collection for Translational Research, LAB03-0976, 2004–present, \$1,533,842 (\$287,596/year), NIH/NCI

Principal Investigator, The Collection and Storage of Umbilical Cord Blood for Transplantation, LAB04-0249, 2004–present, \$3,001,248, HRSA

Principal Investigator, Phase II Study of Parathyroid Hormone following Myeloablative Sequential Unrelated Cord Blood Transplantation, 2006-0569, 2006–2008, U54

Principal Investigator, A Multi-Center, Multi-National, Historical Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx® (Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo) in Subjects with Hematological Malignancies Following Myeloablative Therapy, 2006-0570, 2006–2009, \$250, Gamida Cell

Principal Investigator, Cord Blood Expansion on Mesenchymal Stem Cells, 2005-0781, 2006–present, \$397,550, Viacell Inc, Angioblast

Principal Investigator, The Ex Vivo Expansion of Primitive Cord Blood Progenitors, 2005-0781, 2006–present, Viacell and RO1

Principal Investigator, Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV after Hemopoietic Stem Cell Transplantation (HSCT), 2008-0633, 2008–present, Baylor

Principal Investigator, The Collection and Storage of Related Umbilical Cord Blood for Transplantation, LAB09-0170, 2009–present, HRSA

Principal Investigator, A multicenter access and distribution protocol for unlicensed, 2011-0541, 2011, National Marrow Donor

Principal Investigator, Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients with Hematologic Malignancies, 2010-0658, 2011–present, American Stem Cell, Inc.

Principal Investigator, Randomized, Open Label Controlled Study to Evaluate the Efficacy and Safety of Umbilical Cord Blood Cells Expanded Ex Vivo with Mesenchymal Precursor Cells for Hematopoietic Recovery in Patients With Hematologic Malignancies After Myeloablative Conditioning, 2012-0166, 2013–present, \$1,443,874 (\$721,937/year), Mesoblast

Unfunded

N/A

Patents and Technology Licenses

Patents

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

Standing Member, Cancer League of Colorado, Reviewer, 1994–1997

Standing Member, Susan Komen Foundation for Research Grants, Member, 1995–1998

Standing Member, NIH Cancer Centers and Research Programs Review Committee, Member, 1995–2000

Ad hoc Member, National Heart, Lung and Blood Institute Grant Review Committee, Ad Hoc Member, 1995–present

National Cancer Institute Grant Review, National Cancer Institute Grant Review, Ad Hoc Member, 1995–present

Stem Cell Gene Therapy for Hemoglobinopathies, NHLBI, Review, 2009

Cancer Therapies Special Emphasis Panel, NIH, Member, 2011

MDS Pathophysiology and Therapy, National Heart, Lung and Blood Institute, Emphasis Panel to Review, 2011

NCI PO1 Special Emphasis Panel Review, NIH, Member, 2012

ASH Scholars Grant Review Committee, ASH, Member, 2013

Standing Member, Personalized Cancer Immunotherapy-Genome Canada, Standing Member, 2013–present

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Shpall EJ, Holland JF. Update on understanding the causes of cancer. *Compr Ther* 12:9-14, 8/1986.
2. Shpall EJ, Efremidis AP, Kasambalides E, Sedlin E, Hermann G. Case report 352: Osteonecrosis of the femoral shaft (probably steroid-induced). *Skeletal Radiol* 15(2):170-4, 1986.
3. Shpall EJ, Efremidis AP, Kasmbalides E, Sedlin E, Hermann G. Osteonecrosis of the femoral head. *Skeletal Radiol* 15(2):170-4, 1986.
4. Shpall E, Jones R, Egorin M, Gockerman J, Moore J, Bast R, Olsen G, Coniglio D, Brophy L, Walsh B, Peters W. A phase I trial of high dose combination cyclophosphamide (C), cisplatin (P) and thiotepa (T), with autologous bone marrow support (ABMS) in the treatment of resistant solid tumors. *Proc Amer Soc Clin Oncol* 6:139, 1987.
5. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Jr, Gilbert CJ, Oette DH. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. *N Engl J Med* 318(14):869-76, 4/1988.
6. Shpall EJ, Jones RB, Holland JF, Bhardwaj S, Paciucci PA, Wilfinger CL, Strashun A. Intensive single-agent mitoxantrone for metastatic breast cancer. *J Natl Cancer Inst* 80(3):204-8, 4/1988.
7. Peters WP, Shogan J, Shpall EJ, Jones RB, Kim CS. Recombinant human granulocyte-macrophage colony-stimulating factor produces fever. *Lancet* 1(8591):950, 4/1988.
8. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. *J Clin Oncol* 6(9):1368-76, 9/1988.
9. Anderson IC, Shpall EJ, Leslie DS, Nustad K, Ugelstad J, Peters WP, Bast RC, Jr. Elimination of malignant clonogenic breast cancer cells from human bone marrow. *Cancer Res* 49(16):4659-64, 8/1989.
10. Peters WP, Kurtzberg J, Rao M, Atwater S, Coleman RE, Jones RB, Shpall EJ, Ross M, Affronti ML, Gilbert C, Garnick M. Effects of recombinant human macrophage colony stimulating factor (rHuM-CSF) on hematopoiesis following high-dose chemotherapy (HDC) and autologous bone marrow support (ABMS). *Blood* 74:269-70, 1989.

11. Peters WP, Stuart A, Klotman M, Gilbert C, Jones RB, Shpall EJ, Gockerman J, Bast RC, Jr, Moore JO. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. *Cancer Chemother Pharmacol* 23(6):377-83, 1989.
12. Shpall EJ, Bast RC, Joines W, Jones R, Edwards S, Eggleston S, Johnston C, Peters WP. Large-scale Immunopharmacologic purging of clonogenic cancer cells from bone marrow for autologous bone marrow transplantation (ABMT). *Proc Amer Assoc. Cancer Research* 30:35, 1989.
13. Peters WP, Atwater S, Kurtzberg J, Borowitz M, Brandt SJ, Coleman RE, Kim CS, Gilbert C, Shpall EJ, Jones RB, Shogan J, Oette D, Stuart A, Coniglio D, Affronti ML, Evans S. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. *Bone Marrow Transplantation: Current Controversies*:595-606, 1989.
14. Leslie DS, Johnston WW, Daly L, Ring DB, Shpall EJ, Peters WP, Bast RC, Jr. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. *Am J Clin Pathol* 94(1):8-13, 7/1990.
15. Jones RB, Shpall EJ, Shogan J, Affronti ML, Coniglio D, Hart L, Halperin E, Iglehart JD, Moore J, Gockerman J, et al. The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. *Cancer* 66(3):431-6, 8/1990.
16. Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC, Jr, Ross M, Lidor Y, Vanacek K, Tyler T, et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. *Gynecol Oncol* 38(3):386-91, 9/1990.
17. Jones RB, Shpall EJ, Ross M, Coniglio D, Affronti ML, Peters WP. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. *Cancer Chemother Pharmacol* 26(2):155-6, 1990.
18. Shpall EJ, Bast RC, Joines W, Jones RB, Ross M, Johnston C, Eggleston S, Tepperberg M, Peters WP. Immunopharmacologic Bone Marrow Purging in Metastatic Breast Cancer (CA) patients (pts) Receiving High-Dose Chemotherapy with Autologous Marrow Support (meeting abstract). *Proc Annual Mtg Amer Soc Clin. Oncol* 9:A29, 1990.
19. Shpall EJ, Anderson IC, Bast RC, Jr, Joines WT, Jones RB, Ross M, Edwards S, Eggleston S, Johnston C, Tepperberg M, et al. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. *Prog Clin Biol Res* 333:321-35; discussion 336, 1990.
20. Shpall EJ, Jones RB, Johnston C, Schein P, Peters WP, Seigler H. Purging of breast cancer cells from bone marrow using WR2721 and 4- hydroperoxycyclophosphamide (meeting abstract). *Proc Annual meeting Amer Assoc Cancer Research* 31:A1994, 1990.
21. Peters WP, Kurtzberg J, Atwater S, Borowitz M, Rao M, Currie M, Gilbert C, Shpall EJ, Jones RB, Ross M. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. *Prog Clin Biol Res* 338:121-8, 1990.
22. Shpall EJ, Bast RC, Jr, Joines WT, Jones RB, Anderson I, Johnston C, Eggleston S, Tepperberg M, Edwards S, Peters WP. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. *Bone Marrow Transplant* 7(2):145-51, 2/1991.
23. O'Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC, Jr. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. *Cancer* 68(6):1272-8, 9/1991.
24. Kanj SS, Sharara AI, Shpall EJ, Jones RB, Peters WP. Myocardial ischemia associated with high-dose carmustine infusion. *Cancer* 68(9):1910-2, 11/1991.
25. Lidor YJ, Shpall EJ, Peters WP, Bast RC, Jr. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. *Int J Cancer* 49(5):704-10, 11/1991.
26. Shpall EJ, Jones RB, Bast RC, Jr, Rosner GL, Vandermark R, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperburg M, et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. *J Clin Oncol* 9(1):85-93, 1991.
27. Shpall EJ, Jones RB, Johnston C. Amifostine (WR-2721) shortens recovery of bone purged with 4-HC in breast cancer patients receiving intensive chemotherapy with an autologous bone marrow transplant (ABMT). *Blood* 78:192a, 1991.

28. Shpall EJ, Jones RB, Johnston C, Hami L, Morgan MJ, Stemmer S, Bunn P, Shaw L, McCulloch W, Schein P. WR-2721 (Amifostine) shortens the engraftment period of 4-hydroperoxycyclophosphamide (4-HC) purged bone marrow patients receiving high-dose chemotherapy with autologous bone marrow support (ABMS). *Blood* 78:192a, 1991.
29. Vandemark RM, Shpall EJ, Affronti ML. Bone metastases from breast cancer: value of CT bone windows. *J Comput Assist Tomogr* 16(4):608-14, 7/1992.
30. Johnston CS, Shpall EJ, Williams S, Hami L, Jones RB, Bast RC, Ceriani RL, Franklin W. Detection of minimal residual breast cancer in bone marrow. *Prog Clin Biol Res* 377:637-42, 1992.
31. Antman K, Corringham R, De Vries E, Elfenbein G, Gianni AM, Gisselbrecht C, Herzig R, Juttner C, Kaizer H, Kennedy MJ, Kessinger A, Kotasek D, Lazarus H, Ljungman P, Maraninchi D, Nabholz J, Niederwieser D, Ogawa M, Patrone F, Peters W, Rosti G, Rouesse J, Schilcher R, Selby G, Shea T, Shpall E, Spitzer G, Sweet D, Tajima T, Vaughan W, Williams S, Wolff S. Dose-intensive therapy in breast cancer. *Bone Marrow Transplantation: Current Controversies* 10:67-73, 1992.
32. Shpall EJ. New developments in bone marrow purging strategy: The protection and selection of the Hematopoietic progenitor cell. *Intl Autologous Bone Marrow Transplant Registry Reviews* 5:7-9, 1992.
33. Shpall EJ, Stemmer SM, Johnston CF, Hami L, Bearman SI, Berenson R, Jones RB. Purging of autologous bone marrow for transplantation: the protection and selection of the hematopoietic progenitor cell. *J Hematother* 1(1):45-54, 1992.
34. Shpall EJ, Jones RB, Johnston C. Purified cd34-positive (+) marrow progenitor cells provide effective reconstitution for breast cancer (ca) and non-Hodgkin's lymphoma (nhl) patients receiving high dose chemotherapy with autologous bone marrow support (hdc/abms): recombinant granulocyte colony stimulating factor (g-csf) accelerates hematopoietic recovery. *Proc Amer Soc Clin Oncol* 11:A61, 1992.
35. Hami LS, Shpall EJ, Johnston CS, Berenson R, Jones RB. The effect of PIXY-321 on 4-hydroperoxycyclophosphamide purged and CD34+ positively selected bone marrow. *Prog Clin Biol Res* 377:321-5, 1992.
36. Jones RB, Matthes S, Shpall EJ, Fisher JH, Stemmer SM, Dufton C, Stephens JK, Bearman SI. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. *J Natl Cancer Inst* 85(8):640-7, 4/1993.
37. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jr, Jones R, Shpall E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. *J Clin Oncol* 11(6):1132-43, 6/1993.
38. Shpall EJ, Stemmer SM, Bearman SI, Jones RB. Role of autotransplantation in treatment of other solid tumors. *Hematol Oncol Clin North Am* 7(3):663-86, 6/1993.
39. Meisenberg BR, Ross M, Vredenburgh JJ, Jones R, Shpall EJ, Seigler HF, Coniglio DM, Wu K, Peters WP. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. *J Natl Cancer Inst* 85(13):1080-5, 7/1993.
40. Shpall EJ, Jones RB, Bearman SI, Stemmer SM, Purdy MH, Heimfeld S, Berenson RJ. Positive selection of CD34+ hematopoietic progenitor cells for transplantation. *Stem Cells* 11 Suppl 3:48-9, 10/1993.
41. Shpall EJ, Stemmer SM, Bearman SI, Myers S, Purdy M, Jones RB. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. *Breast Cancer Res Treat* 26 Suppl:S19-23, 1993.
42. Jones RB, Matthes S, Dufton C, Bearman SI, Stemmer SM, Meyers S, Shpall EJ. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. *Breast Cancer Res Treat* 26 Suppl:S11-7, 1993.
43. Shpall EJ, Jones RB, Bearman S, Franklin WA, Stemmer S, Archer PA. Transplantation of autologous CD34+ hematopoietic progenitor cells into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. *J Clin Oncol* 12:28-36, 1993.
44. Shpall EJ, Jones RB. Release of tumor cells from bone marrow. *Blood* 83(3):623-5, 2/1994.

45. Shpall EJ, Jones RB, Bearman S. High-dose therapy with autologous bone marrow transplantation for the treatment of solid tumors. *Curr Opin Oncol* 6(2):135-8, 3/1994.
46. Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC, Jr, McCulloch W, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. *Blood* 83(11):3132-7, 6/1994.
47. Bitter MA, Fiorito D, Corkill ME, Huffer WE, Stemmer SM, Shpall EJ, Archer PG, Franklin WA. Bone marrow involvement by lobular carcinoma of the breast cannot be identified reliably by routine histological examination alone. *Hum Pathol* 25(8):781-8, 8/1994.
48. Shpall EJ, Jones RB, Bearman SI, Purdy MP. Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. *Gynecol Oncol* 54(3):357-61, 9/1994.
49. Shpall EJ, Gehling U, Cagnoni P, Purdy M, Hami L, Gee AP. Isolation of CD34-positive hematopoietic progenitor cells. *Immunomethods* 5(3):197-203, 12/1994.
50. Morstyn G, Glaspy J, Shpall EJ, LeMaistre F, Briddell R, Menchaca D, Lill M, Jones RB, Tami J, Brown S, et al. Clinical applications of filgrastim and stem cell factor in vivo and in vitro. *J Hematother* 3(4):353-5, 1994.
51. Petsche D, Hami L, Purdy M, Myers S, Hogan C, Messner H, Briddell R, Heimfeld S, Berenson R, Shpall E. Comparative assays of megakaryocyte progenitors in CD34+ peripheral blood progenitor cell fractions. *Prog Clin Biol Res* 389:415-20, 1994.
52. Petsche D, Hami L, Purdy M, Myers S, Hogan C, Messner H, Briddell R, Heimfeld S, Berenson R, Shpall EJ. Comparative assays of megakaryocyte progenitors in CD34+ peripheral blood progenitor cell fractions. *Prog Clin Biol Res* 389:415-20, 1994.
53. Jones RB, Shpall EJ. Dissemination and commercialization of hematopoietic progenitor cell transplantation. *J Hematother* 3(2):93-4, 1994.
54. Purdy MH, Shpall EJ. The role and methodology for purging tumor from autologous bone marrow and peripheral blood progenitor cells. *Med Oncol* 11(2):47-51, 1994.
55. Shpall EJ, Franklin WA, Jones RB, Bearman SI, Purdy MH, Cagnoni P, Heimfeld S, Berenson RJ. Transplantation of CD34 positive (+) marrow and/or peripheral blood progenitor cells (PBPCS) into breast cancer patients following high-dose chemotherapy. *Blood* 84(10):396a, 1994.
56. Shpall EJ, Jones RB, Bearman SI, Purdy MH, Franklin WA, Heimfeld S, Berenson RJ. Transplantation of CD34+ hematopoietic progenitor cells. *J Hematother* 3(2):145-7, 1994.
57. Shpall EJ, Jones RB, Bearman SI, Purdy MH, Franklin WA, Heimfeld S, Berenson RJ. Transplantation of CD34+ hematopoietic progenitor cells: Implications for removal of tumor cells. *Hematology/Oncology Annals* 2(1):78-84, 1994.
58. Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy M, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. *J Clin Oncol* 12(1):28-36, 1994.
59. Appelbaum F, Fay J, Herzig G, Kersey J, Parkman R, Petersdorf E, Przepiorka D, Saral R, Shpall E, Wolf J. American Society for Blood and Marrow Transplantation guidelines for training. *Biol Blood Marrow Transplant* 1(1):56, 11/1995.
60. Harrison GS, Wang Y, Tomczak J, Hogan C, Shpall EJ, Curiel TJ, Felgner PL. Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells. *Biotechniques* 19(5):816-23, 11/1995.
61. Schrier DM, Stemmer SM, Johnson T, Kasliwal R, Lear J, Matthes S, Taffs S, Dufton C, Glenn S, Butchko G, Ceriani R, Rovira D, Bunn P, Shpall EJ, Bearman SI, Purdy M, Cagnoni P, Jones RB. High-dose 90Y Mx-DTPA-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: A Phase I Trial. *Cancer Research (Suppl)* 55(23):5921-24s, 1995.
62. Purdy MH, Hogan CJ, Hami L, McNiece I, Franklin W, Jones RB, Bearman SI, Berenson RJ, Cagnoni PJ, Heimfeld S, Shpall EJ. Large volume ex vivo expansion of CD34-positive hematopoietic progenitor cells for transplantation. *J Hematother* 4(6):515-25, 1995.

63. Conneally E, Bardy P, Eaves CJ, Thomas T, Chappel S, Shpall EJ, Humphries RK. Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer. *Blood* 87(2):456-64, 1/1996.
64. Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Ross M. High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. *Semin Oncol* 23(1 Suppl 2):60-7, 2/1996.
65. Cagnoni PJ Shpall EJ. Mobilization and selection of CD34-positive hematopoietic progenitors. *Blood Rev* 10(1):1-7, 3/1996.
66. Shpall EJ, Gee AP, Hogan C, Cagnoni P, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB. Bone marrow metastases. *Hematol Oncol Clin North Am* 10(2):321-43, 4/1996.
67. Stemmer SM, Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Dufton C, Day T, Taffs S, Hami L, Martinez C, Purdy MH, Arron J, Jones RB. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. *J Clin Oncol* 14(5):1463-72, 5/1996.
68. Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, Capizzi R, Schein PS, Shpall EJ. Use of amifostine in bone marrow purging. *Semin Oncol* 23(4 Suppl 8):44-8, 8/1996.
69. Cagnoni PJ, Shpall EJ, Bearman SI, Ross M, Jones RB. High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results. *Bone Marrow Transplant* 18 Suppl 1:S26-9, 9/1996.
70. Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. *Kidney Int* 50(3):1026-31, 9/1996.
71. Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Ross M, Taffs S, Jones RB. Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. *Semin Oncol* 23(6 Suppl 15):43-8, 12/1996.
72. Hussein AM, Petros WP, Ross M, Vredenburgh JJ, Affrontil ML, Jones RB, Shpall EJ, Rubin P, Elkordy M, Gilbert C, Gupton C, Egorin MJ, Soper J, Berchuck A, Clarke-Person D, Berry DA, Peters WP. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. *Cancer Chemother Pharmacol* 37(6):561-8, 1996.
73. Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L, Bitter MA, Bast RC, Jones RB. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. *Breast Cancer Res Treat* 41(1):1-13, 1996.
74. Shpall EJ. Peripheral blood progenitor cells harvesting. *Hematopoietic Therapy Index & Reviews* 3(2), 1996.
75. Emerman JT, Stingl J, Petersen A, Shpall EJ, Eaves CJ. Selective growth of freshly isolated human breast epithelial cells cultured at low concentrations in the presence or absence of bone marrow cells. *Breast Cancer Res Treat* 41(2):147-59, 1996.
76. Berenson RJ, Shpall EJ, Auditore-Hargreaves K, Heimfeld S, Jacobs C, Krieger MS. Transplantation of CD34+ hematopoietic progenitor cells. *Cancer Invest* 14(6):589-96, 1996.
77. Cagnoni PJ Shpall EJ. High-dose chemotherapy for the treatment of breast and ovarian cancer. *Curr Opin Oncol* 9(2):122-5, 3/1997.
78. Hogan CJ, Shpall EJ, McNulty O, McNiece I, Dick JE, Shultz LD, Keller G. Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. *Blood* 90(1):85-96, 7/1997.
79. Shpall EJ. Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket no. 97N-0068). FAHCT Board of Directors. *J Hematother* 6(4):287-9, 8/1997.
80. Gehling UM, Ryder JW, Hogan CJ, Hami L, McNiece I, Franklin W, Williams S, Helm K, King J, Shpall EJ. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. *Exp Hematol* 25(11):1125-39, 10/1997.
81. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece IK. Peripheral blood progenitor cell mobilization

- using stem cell factor in combination with filgrastim in breast cancer patients. *Blood* 90(8):2939-51, 10/1997.
82. Campain JA, Terrell KL, Tomczak JA, Shpall EJ, Hami LS, Harrison GS. Comparison of retroviral-mediated gene transfer into cultured human CD34+ hematopoietic progenitor cells derived from peripheral blood, bone marrow, and fetal umbilical cord blood. *Biol Blood Marrow Transplant* 3(5):273-81, 11/1997.
 83. Hogan CJ, Shpall EJ, McNiece I, Keller G. Multilineage engraftment in NOD/LtSz-scid/scid mice from mobilized human CD34+ peripheral blood progenitor cells. *Biol Blood Marrow Transplant* 3(5):236-46, 11/1997.
 84. Shpall EJ, LeMaistre CF, Holland K, Ball E, Jones RB, Saral R, Jacobs C, Heimfeld S, Berenson R, Champlin R. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. *Blood* 90(11):4313-20, 12/1997.
 85. Bearman SI, Overmoyer BA, Bolwell BJ, Taylor CW, Shpall EJ, Cagnoni PJ, Mechling BE, Ronk B, Baron AE, Purdy MH, Ross M, Jones RB. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. *Bone Marrow Transplant* 20(11):931-7, 12/1997.
 86. Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, Sullivan KM. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant* 3(6):331-40, 12/1997.
 87. Nieto Y, Cagnoni PJ, Shpall EJ, Bearman SI, Ross M, Sedlacek S, Jones RB. High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) for inflammatory breast cancer. *Breast Cancer Res Treat* 46(1):72, 1997.
 88. Banda NK, Tomczak JA, Shpall EJ, Sipple J, Akkina RK, Steimer KS, Hami L, Curiel TJ, Singer Harrison G. HIV-gp120 induced cell death in hematopoietic progenitor CD34+ cells. *Apoptosis* 2(1):61-8, 1997.
 89. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB. Peripheral blood stem cell harvesting and CD34-positive cell selection. *Cancer Treat Res* 77:143-57, 1997.
 90. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Jones RB. Peripheral blood stem cells for autografting. *Annu Rev Med* 48:241-51, 1997.
 91. Pugh RE, Bitter MA, Shpall EJ, Hami LS, Wolf DM, Franklin WA. CD19 selection improves the sensitivity of B cell lymphoma detection. *J Hematother* 7(2):159-68, 4/1998.
 92. Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Baron AE, Ross M, Matthes S, Dunbar SE, Jones RB. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. *J Clin Oncol* 16(5):1661-8, 5/1998.
 93. Banda NK, Akkina RK, Terrell K, Shpall EJ, Tomczak J, Campain J, Claman H, Cagle L, Harrison GS. Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model. *J Hematother* 7(4):319-31, 8/1998.
 94. Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. *Biol Blood Marrow Transplant* 4(2):84-92, 1998.
 95. Glick HA, Shpall EJ, LeMaistre CF, McCarron TJ, Lu ZJ, Erder MH, Glaspy JA. Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. *Int J Technol Assess Health Care* 14(3):419-30, 1998.
 96. Nieto Y, Cagnoni PJ, Shpall EJ. High-dose chemotherapy in gynecologic malignancies. *Cancer Treat Res* 95:277-85, 1998.
 97. Hayward A, Ambruso D, Battaglia F, Donlon T, Eddelman K, Giller R, Hobbins J, Hsia YE, Quinones R, Shpall E, Trachtenberg E, Giardina P. Microchimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1. *Fetal Diagn Ther* 13(1):8-14, 1998.
 98. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, DeBoom T, Baron A, Jones RB. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. *Clin Cancer Res* 5(3):501-6, 3/1999.
 99. Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McNiece IK. Peripheral blood stem cell transplantation in breast cancer. *Baillieres Best Pract Res Clin Haematol* 12(1-2):219-32, 3/1999.

100. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, Shea TC, Mangan KF, Williams SF, LeMaistre CF, Long GD, Jones R, Davis MW, Murphy-Filkins R, Parker WR, Glaspy JA. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. *Blood* 93(8):2491-501, 4/1999.
101. Bachier CR, Gokmen E, Teale J, Lanzkron S, Childs C, Franklin W, Shpall E, Douville J, Weber S, Muller T, Armstrong D, LeMaistre CF. Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer. *Exp Hematol* 27(4):615-23, 4/1999.
102. McNiece I, Jones R, Cagnoni P, Bearman S, Nieto Y, Shpall EJ. Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. *Hematol Cell Ther* 41(2):82-6, 4/1999.
103. Nieto Y, Xu X, Cagnoni PJ, Matthes S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. *Clin Cancer Res* 5(4):747-51, 4/1999.
104. Shpall EJ. The utilization of cytokines in stem cell mobilization strategies. *Bone Marrow Transplant* 23 Suppl 2:S13-9, 5/1999.
105. Nieto Y, Ross M, Gianani R, Shpall EJ, Cagnoni PJ, Bearman SI, Jones RB. Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant. *Bone Marrow Transplant* 23(12):1323-4, 6/1999.
106. Franklin WA, Glaspy J, Pflaumer SM, Jones RB, Hami L, Martinez C, Murphy JR, Shpall EJ. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. *Blood* 94(1):340-7, 7/1999.
107. Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. *Bone Marrow Transplant* 24(1):1-4, 7/1999.
108. Nieto Y, Cagnoni PJ, Shpall EJ, Matthes S, Baron A, Jones RB, Bearman SI. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. *Clin Cancer Res* 5(7):1731-7, 7/1999.
109. Bearman SI, Vredenburgh J, Cagnoni P, Shpall E, Nieto Y, Ross M, Peters W, Jones R. High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. *Bone Marrow Transplant* 24(5):491-5, 9/1999.
110. Nieto Y, Shpall EJ. Autologous stem-cell transplantation for solid tumors in adults. *Hematol Oncol Clin North Am* 13(5):939-68, vi, 10/1999.
111. Johnson DW, Cagnoni PJ, Schossau TM, Stemmer SM, Grayeb DE, Baron AE, Shpall EJ, Bearman SI, McDermitt J, Jones RB. Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support. *Bone Marrow Transplant* 24(7):785-92, 10/1999.
112. Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. *J Clin Oncol* 17(10):3064-74, 10/1999.
113. Nieto Y, Cagnoni PJ, Shpall EJ, Xu X, Murphy J, Vredenburgh J, Chao NJ, Bearman SI, Jones RB. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. *Clin Cancer Res* 5(11):3425-31, 11/1999.
114. Banda NK, Simon GR, Sipple JD, Terrell KL, Archer P, Shpall EJ, Akkina RK, Myers AM, Harrison GS. Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals. *Biol Blood Marrow Transplant* 5(3):162-72, 1999.
115. Berenson RJ, Heimfeld S, Auditore-Hargreaves K, Krieger M, Jacobs C, Shpall EJ. Hematopoietic stem cell transplantation. *J Hematotherapy*, 1999.
116. Nieto Y, Ross M, Gianani RCagnoni PJ, Shpall EJ, Bearman SI, Jones RB. Isolated cytomegalovirus oophoritis after allogeneic peripheral blood progenitor cell transplant. *Bone Marrow Transplant* 23:1323-1324, 1999.

117. Stiff P, Chen B, Franklin W, Oldenberg D, Hsi E, Bayer R, Shpall E, Douville J, Mandalam R, Malhotra D, Muller T, Armstrong RD, Smith A. Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer. *Blood* 95(6):2169-74, 3/2000.
118. Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman SI, Jones RB. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. *J Clin Oncol* 18(10):2070-80, 5/2000.
119. Nieto Y, Russ P, Everson G, Bearman SI, Cagnoni PJ, Jones RB, Shpall EJ. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. *Bone Marrow Transplant* 26(1):109-11, 7/2000.
120. McNiece I, Kubegov D, Kerzic P, Shpall EJ, Gross S. Increased expansion and differentiation of cord blood products using a two-step expansion culture. *Exp Hematol* 28(10):1181-6, 10/2000.
121. McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W, Ryder J, Steele A, Stoltz J, Russell P, McDermit J, Hogan C, Murphy J, Shpall EJ. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. *Blood* 96(9):3001-7, 11/2000.
122. Howrey RP, Martin PL, Driscoll T, Szabolcs P, Kelly T, Shpall EJ, Bearman SI, Slat-Vasquez V, Rubinstein P, Stevens CE, Kurtzberg J. Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia. *Bone Marrow Transplant* 26(11):1251-4, 12/2000.
123. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. *Biol Blood Marrow Transplant* 6(2A):198-203, 2000.
124. Nieto Y, Shpall EJ. High-dose chemotherapy for breast cancer. *Cancer Treat Res* 103:77-114, 2000.
125. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EF. Status of high-dose chemotherapy for breast cancer: a review. *Biol Blood Marrow Transplant* 6(5):476-95, 2000.
126. Shpall EJ, Quinones R, Giller R, Jones RB, Bearman SI, Nieto Y, McSweeney P, Cagnoni P, Baron A, Zeng C, Madinger N, Hogan C, Ward B, Slat-Vasquez V, Russell P, Blunk B, Solzan M, McNiece I. Transplantation of adult and pediatric cancer patients with cord blood progenitors expanded ex vivo. *Blood (mtg abstract)* 96(11):207a, 2000.
127. Shpall EJ, Quinones R, Giller R. Transplantation of Ex Vivo Expanded Cord Blood. *Biol Blood Marrow Transp* 8:368-376, 2000.
128. Nieto Y, Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Rabinovitch RA, McSweeney PA. Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft. *Bone Marrow Transplant* 28(11):1083-6, 12/2001.
129. Shpall E, Adkins D, Appelbaum F, Keating A, LeMaistre CF, Mangan K, Smith F. American Society for Blood and Marrow Transplantation guidelines for training. *Biol Blood Marrow Transplant* 7(10):577, 2001.
130. Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. *Proc Natl Acad Sci U S A* 99(1):413-8, 1/2002. PMID: PMC117574.
131. Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Baron A, Razook C, Matthes S, Bearman SI. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. *J Clin Oncol* 20(3):707-18, 2/2002.
132. McNiece IK, Almeida-Porada G, Shpall EJ, Zanjani E. Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long-term engrafting potential. *Exp Hematol* 30(6):612-6, 6/2002.
133. Yago Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Baron A, Razook C, Matthes S, Bearman SI. Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer. *J Clin Oncol* 20(3):707-718, 2002.

134. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK. Transplantation of ex vivo expanded cord blood. *Biol Blood Marrow Transplant* 8(7):368-76, 2002.
135. Medeiros BC, Kolhouse JF, Cagnoni PJ, Ryder J, Nieto Y, Rabinovitch R, Shpall EJ, Bearman SI, Jones RB, McSweeney PA. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. *Bone Marrow Transplant* 31(11):1053-5, 6/2003.
136. Suratt BT, Cool CD, Serls AE, Chen L, Varella-Garcia M, Shpall EJ, Brown KK, Worthen GS. Human pulmonary chimerism after hematopoietic stem cell transplantation. *Am J Respir Crit Care Med* 168(3):318-22, 8/2003.
137. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. *Leukemia* 17(12):2538-40, 12/2003.
138. Nieto Y, Nawaz S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. *Clin Cancer Res* 10(8):2609-17, 4/2004.
139. Nieto Y, Franklin WA, Jones RB, Berman SI, Pellom J, Baron AE, Shpall EJ. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. *Biol Blood Marrow Transplant* 10(6):415-25, 6/2004.
140. de Lima M, Shpall EJ. Ex-vivo purging of hematopoietic progenitor cells. *Curr Hematol Rep* 3(4):257-64, 7/2004.
141. Stiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh AR, Samlowski W, McCoy J, Alberts DS. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. *Gynecol Oncol* 94(1):98-106, 7/2004.
142. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. *Blood* 104(3):857-64, 8/2004.
143. Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, Pellom J, Slat-Vasquez V, McSweeney PA, Bearman SI, Murphy J, Jones RB. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. *Clin Cancer Res* 10(15):5076-86, 8/2004.
144. Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Chao N, Rizzieri D, Gasparetto C, Matthes S, Baron AE, Jones RB. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. *Clin Cancer Res* 10(21):7136-43, 11/2004.
145. Nieto Y, Jones RB, Shpall EJ. Stem-cell transplantation for the treatment of advanced solid tumors. *Springer Semin Immunopathol* 26(1-2):31-56, 11/2004.
146. Cheng YC, Rondon G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. *Biol Blood Marrow Transplant* 10(11):794-804, 11/2004.
147. Shpall EJ, Ginsberg DA. Bladder neck closure with lower urinary tract reconstruction: technique and long-term followup. *The Journal of Urology* 172(6.1):2004, 2004.
148. McNiece I, Harrington J, Turney J, Kellner J, Shpall EJ. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. *Cytotherapy* 6(4):311-7, 2004.
149. Peled T, Mandel J, Goudsmid RN, Landor C, Hasson N, Harati D, Austin M, Hasson A, Fibach E, Shpall EJ, Nagler A. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. *Cytotherapy* 6(4):344-55, 2004.

150. Weinberg A, Enomoto L, Li S, Shen D, Coll J, Shpall EJ. Risk of transmission of herpesviruses through cord blood transplantation. *Biol Blood Marrow Transplant* 11(1):35-8, 1/2005.
151. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. *J Clin Oncol* 23(10):2240-7, 4/2005.
152. Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Baron AE, Jones RB. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. *Biol Blood Marrow Transplant* 11(4):297-306, 4/2005.
153. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. *J Clin Oncol* 23(10):2191-200, 4/2005.
154. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR, Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. *Biol Blood Marrow Transplant* 11(5):389-98, 5/2005.
155. Nieto Y, Shpall EJ, Bearman SI, Jones RB. Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. *Am J Clin Oncol* 28(3):248-54, 6/2005.
156. Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, Zeng C, Baron A, McSweeney PA. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. *Bone Marrow Transplant* 36(5):443-51, 9/2005.
157. Rosinski SL, McNiece IK, Shpall EJ, Clough N, Russell P, Blunk B, Nieto Y. Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. *Bone Marrow Transplant* 36(5):425-30, 9/2005.
158. Peppercorn J, Herndon J, 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. *Cancer* 104(8):1580-9, 10/2005.
159. Nieto Y, Shpall EJ, Bearman SI, Jones RB. Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. *Amer J Clin Oncol* 28(3):248-54, 2005.
160. Robinson S, Niu T, de Lima M, Ng J, Yang H, McMannis J, Karandish S, Sadeghi T, Fu P, del Angel M, O'Connor S, Champlin R, Shpall E. Ex vivo expansion of umbilical cord blood. *Cytotherapy* 7(3):243-50, 2005.
161. Korbling M, Robinson S, Estrov Z, Champlin R, Shpall E. Umbilical cord blood-derived cells for tissue repair. *Cytotherapy* 7(3):258-61, 2005.
162. Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, Hussein A, Rizzieri D, Marks LB, Gilbert C, Affronti ML, Moore S, McDonald C, Petros WP, Peters WP. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. *Biol Blood Marrow Transplant* 12(2):195-203, 2/2006.
163. Decker WK, Xing D, Shpall EJ. Dendritic cell immunotherapy for the treatment of neoplastic disease. *Biol Blood Marrow Transplant* 12(2):113-25, 2/2006.
164. Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, Kaur I, Fu P, Del Angel M, Messinger R, Flagg F, de Lima M, Decker W, Xing D, Champlin R, Shpall EJ. Superior ex vivo

- cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. *Bone Marrow Transplant* 37(4):359-66, 2/2006. PMID: PMC1885539.
165. Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, Shpall EJ, Rabinovitch R, Zeng C, Baron A, McSweeney PA. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. *Biol Blood Marrow Transplant* 12(2):217-25, 2/2006.
 166. Thall PF, Wooten LH, Shpall EJ. A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases. *Biometrics* 62:193-201, 3/2006. e-Pub.
 167. Yang H, Eaves C, de Lima M, Lee MS, Champlin RE, McMannis JD, Robinson SN, Niu T, Decker WK, Xing D, Ng J, Li S, Yao X, Eaves AC, Jones R, Andersson BS, Shpall EJ. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. *Bone Marrow Transplant* 37(6):575-82, 3/2006.
 168. Decker WK, Xing D, Li S, Robinson SN, Yang H, Yao X, Segall H, McMannis JD, Komanduri KV, Champlin RE, Shpall EJ. Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. *Vaccine* 24(16):3203-16, 4/2006. e-Pub 1/2006.
 169. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. *Blood* 107(8):3074-80, 4/2006.
 170. de Lima M, Shpall E. Strategies for widening the use of cord blood in hematopoietic stem cell transplantation. *Haematologica* 91(5):584-7, 5/2006.
 171. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Korbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. *Br J Haematol* 133(5):533-7, 6/2006.
 172. Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. *Cancer* 106(12):2664-71, 6/2006.
 173. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. *Bone Marrow Transplant* 38(6):421-6, 9/2006.
 174. Wang S, Hong S, Yang J, Qian J, Zhang X, Shpall E, Kwak LW, Yi Q. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. *Blood* 108(13):4071-7, 12/2006.
 175. Xing D, Decker WK, Li S, Robinson SN, Yang H, Segal H, O'Connor S, Yao X, Komanduri KV, McMannis JD, Jones RB, de Lima M, Champlin RE, Shpall EJ. AML-loaded DC generate Th1-type cellular immune responses in vitro. *Cytotherapy* 8(2):95-104, 2006.
 176. Parmar S, Robinson SN, Komanduri K, St John L, Decker W, Xing D, Yang H, McMannis J, Champlin R, de Lima M, Mollndrem J, Rieber A, Bonyhadi M, Berenson R, Shpall EJ. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. *Cytotherapy* 8(2):149-57, 2006.
 177. Couriel D, Hosing C, Saliba R, Shpall EJ, Anderlini P, Popat U, Donato M, Champlin R. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? *Biol Blood Marrow Transplant* 12(1 Suppl 2):37-40, 2006.
 178. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, Pierre B, Shpall EJ, Jones RB, Champlin RE, Andersson BS. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. *Biol Blood Marrow Transplant* 13(1):56-64, 1/2007.
 179. Shpall EJ, Safdar A, Rodriguez G. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. *Bone Marrow Transplant* 39(3):157-64, 2/2007.

180. Shpall EJ, Oran B., Donato M. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. *Biol. Blood Marrow Transplant* 13(4):469-477, 2/2007. e-Pub 2/2007.
181. Shpall EJ, Zhang S, Willerson JT. Fusion of human hematopoietic progenitor cells and murine cardiomyocytes is mediated by alpha 4 beta 1 integrin/vascular cell adhesion molecule-1 interaction. *Circulation Research* 100(5):693-702, 3/2007. e-Pub 2/2007.
182. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. *Cancer* 110(2):340-4, 7/2007.
183. Shpall EJ, Ballen, K.K. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. *Biology of Blood and Marrow Transplantation* 13(7):838-843, [http://linkinghub.elsevier.com/retrieve/pii/S1083-8791\(07\)00216-9](http://linkinghub.elsevier.com/retrieve/pii/S1083-8791(07)00216-9), 7/2007. e-Pub 4/2007.
184. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. *Br J Cancer* 97(3):391-397, <http://www.nature.com/bjc/journal/v97/n3/pdf/6603875a.pdf>, 7/2007.
185. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. *Bone Marrow Transplant* 40(2):125-36, 7/2007. e-Pub 5/2007.
186. Patah PA, Parmar S, McMannis J, Sadeghi T, Karandish S, Rondon G, Tarrand J, Champlin R, de Lima M, Shpall EJ. Microbial contamination of hematopoietic progenitor cell products: Clinical outcome. *Bone Marrow Transplant* 40(4):365-368, 8/2007.
187. Sims CR, Thompson K, Chemaly RF, Shpall EJ, Champlin RE, Safdar A. Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection. *Transpl Infect Dis* 9(3):256-9, 9/2007.
188. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. *J Clin Oncol* 25(28):4405-13, 10/2007.
189. Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL, Shpall EJ, Rolston KV, Raad II, Chan KW, Champlin RE. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. *Medicine* 86(6):324-333, 11/2007.
190. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG, Kaur I, Martin S, Wieder ED, Worth L, Cooper LJ, Petropoulos D, Molldrem JJ, Champlin RE, Shpall EJ. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T cell skewing. *Blood* 110(13):4543-51, 12/2007. e-Pub 8/2007. PMID: PMC2234787.
191. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. *Leukemia* 21(12):2540-4, 12/2007.
192. Decker WK, Li S, Xing D, Robinson SN, Yang H, Steiner D, Komanduri KV, Bollard CM, Shpall EJ. Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cells. *J Immunother* 31(2):157-65, Feb-Mar, 2/2008.
193. Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC Jr, Ross M, Lidor Y, Vanacek K, Tyler T, et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. *Gynecol Oncol* 38(3):386-91, 2/2008.
194. Decker WK, Shpall EJ. Progress in dendritic cell immunotherapy: elucidating the enigma of Th-1 polarization. *Hum Vaccin* 4(2):162-4, 3/2008. e-Pub 9/2007.
195. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. *Cancer Res* 68(8):2961-71, 4/2008. PMID: PMC2424272.

196. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. *Bone Marrow Transplant* 41(9):771-8, 5/2008.
197. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. *Biol Blood Marrow Transplant* 14(6):672-84, 6/2008.
198. Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. *Biol Blood Marrow Transplant* 14(8):859-66, 8/2008.
199. Ni X, Richmond HM, Liao XM, Decker WK, Shiue LH, Shpall EJ, Duvic M. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. *J Invest Dermatol* 128(11):2631-9, 11/2008. e-Pub 5/2008.
200. De Assis RA, Kerbauy FR, Rodrigues M, Seguro FS, Aranha LF, Fayad L, Shpall EJ, de Lima M, Hamerschlak N. Mycobacterium tuberculosis infection: a rare late complication after cord blood hematopoietic SCT. *Bone Marrow Transplant* 43(8):667-8. e-Pub 11/2008.
201. Gonzalez G, Shpall EJ, Gathe JC, Behringer RR. Cord blood stem cell therapy for acquired immune deficiency syndrome. *Stem Cells Dev* 18(1):1-2, Jan-Feb, 1/2009. e-Pub 11/2008.
202. Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. *Haematologica* 94(2):249-57, 2/2009. e-Pub 1/2009. PMID: PMC2635398.
203. Safdar A, Decker WK, Li S, Xing D, Robinson SN, Yang H, Steiner D, Rodriguez G, Shpall EJ, Bollard C. De novo T-lymphocyte responses against baculovirus-derived recombinant influenza virus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination. *Vaccine* 27(10):1479-84, 3/2009. e-Pub 2/2009.
204. Nieto Y, Shpall EJ. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? *Curr Opin Oncol* 21(2):150-7, 3/2009.
205. Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H, Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJ. PET imaging of T cells derived from umbilical cord blood. *Leukemia* 23(3):620-2. e-Pub 3/2009.
206. Decker WK, Xing D, Li S, Robinson SN, Yang H, Steiner D, Komanduri KV, Shpall EJ. Th-1 polarization is regulated by dendritic cell comparison of MHC class I and class II antigens. *Blood* 113(18):4213-23, 4/2009. e-Pub 1/2009. PMID: PMC2676083.
207. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. *Cancer* 115(9):1899-905, 5/2009. e-Pub 2/2009.
208. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. *Biol Blood Marrow Transplant* 15(6):718-23, 6/2009. e-Pub 4/2009.
209. Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. *Biol Blood Marrow Transplant* 15(7):777-84, 7/2009. e-Pub 5/2009. PMID: PMC2814363.
210. Dotti G, Tian M, Savoldo B, Najjar A, Cooper LJ, Jackson J, Smith A, Mawlawi O, Uthamanthil R, Borne A, Brammer D, Paolillo V, Alauddin M, Gonzalez C, Steiner D, Decker WK, Marini F, Kornblau S, Bollard CM, Shpall EJ, Gelovani JG. Repetitive Noninvasive Monitoring of HSV1-tk-Expressing T Cells Intravenously Infused into Nonhuman Primates Using Positron Emission Tomography and Computed Tomography with 18F-FEAU. *Mol Imaging* 8(4):230-7, Jul-Aug, 7/2009.

211. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. *Blood* 114(9):1958-67, 8/2009. e-Pub 5/2009. PMID: PMC2738578.
212. Steiner D, Gelovani J, Savoldo B, Robinson SN, Decker WK, Brouard N, Najjar A, Xing D, Yang H, Li S, Marini F, Zweidler-McKay PA, Bollard CM, Shpall EJ, Dotti G, Simmons PJ. Noninvasive Bioluminescent Imaging Demonstrates Long-Term Multilineage Engraftment of Ex Vivo-Expanded CD34-Selected Umbilical Cord Blood Cells. *Stem Cells* 27(8):1932-1940, 8/2009. e-Pub 4/2009.
213. Ciurea SO, Saliba R, Rondon G, Pessoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, Lima MD, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiopeta for adult patients undergoing haploidentical SCT. *Bone Marrow Transplant*. e-Pub 8/2009.
214. Shah N, Shpall EJ. NK antibody therapy: KIR-ative intent. *Blood* 114(13):2567-8, 9/2009.
215. Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pessoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. *Blood* 114(14):2884-7, 10/2009. e-Pub 8/2009.
216. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. *Transplantation* 88(8):1019-24, 10/2009.
217. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi A. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. *Biol Blood Marrow Transplant* 15(12):1555-62, 12/2009. e-Pub 9/2009.
218. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. *Clin Lymphoma Myeloma* 9 Suppl 3:S261-5, 2009.
219. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. *Blood* 115(13):2695-703, 4/2010. e-Pub 1/2010. PMID: PMC2852368.
220. Marks LB, Cirincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson IC, Hurd DD, Peters WP, Cancer and Leukemia Group B, Southwest Oncology Group, National Cancer Institute of Canada Clinical Trials Group. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. *Int J Radiat Oncol Biol Phys* 76(5):1305-13, 4/2010. e-Pub 9/2009.
221. Kelly SS, Parmar S, De Lima M, Robinson S, Shpall E. Overcoming the barriers to umbilical cord blood transplantation. *Cytotherapy* 12(2):121-30, 4/2010.
222. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. PiggyBac transposon/transposase system to generate CD19-specific T cells for treatment of B-lineage malignancies. *Hum Gene Ther* 21(4):427-37, 4/2010. e-Pub 11/2009. PMID: PMC2938363.
223. Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved hepatitis B virus infection is not associated with worse outcomes after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 16(5):686-94, 5/2010. e-Pub 1/2010.

224. Yang H, Robinson SN, Lu J, Decker WK, Xing D, Steiner D, Parmar S, Shah N, Champlin RE, Munsell M, Leen A, Bollard C, Simmons PJ, Shpall EJ. CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields. *Bone Marrow Transplant* 45(6):1000-7, 6/2010. e-Pub 10/2009. PMID: PMC3179274.
225. Wang J, Zhang S, Rabinovich B, Bidaut L, Soghomonyan S, Alauddin MM, Bankson JA, Shpall E, Willerson JT, Gelovani JG, Yeh ET. Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action. *Circ Res* 106(12):1904-11, 6/2010. e-Pub 5/2010. PMID: PMC2908245.
226. Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, Han XY, Tarrand J, Ribeiro R, Gulbis A, Shpall EJ, Jones R, Popat U, Walker JA, Petropoulos D, Chiattonne A, Stewart J, El-Zimaity M, Anderlini P, Giralt S, Champlin RE, de Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. *Haematologica* 95(7):1183-90, 7/2010. e-Pub 4/2010. PMID: PMC2895044.
227. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. *Leuk Lymphoma* 51(8):1478-84, 8/2010.
228. Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion. *J Immunother* 33(7):684-96, 9/2010. e-Pub 7/2010.
229. Wierda WG, Chiorazzi N, Dearden C, Brown JR, Montserrat E, Shpall E, Stilgenbauer S, Muneer S, Grever M. Chronic lymphocytic leukemia: new concepts for future therapy. *Clin Lymphoma Myeloma Leuk* 10(5):369-78, 10/2010.
230. Hanley PJ, Cruz CR, Shpall EJ, Bollard CM. Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. *Cytotherapy* 12(6):713-20, 10/2010.
231. Bashir Q, Robinson SN, de Lima MJ, Parmar S, Shpall E. Umbilical cord blood transplantation. *Clin Adv Hematol Oncol* 8(11):786-801, 11/2010.
232. Cohen YC, Scaradavou A, Stevens CE, Rubinstein P, Gluckman E, Rocha V, Horowitz MM, Eapen M, Nagler A, Shpall EJ, Laughlin MJ, Daniely Y, Pacheco D, Barishev R, Olmer L, Freedman LS. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. *Bone Marrow Transplant* 46(1):70-6, 1/2011. e-Pub 5/2010.
233. Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RE. Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. *Leuk Lymphoma* 52(1):137-41, 1/2011. e-Pub 10/2010.
234. Shpall EJ, Bollard CM, Brunstein C. Novel cord blood transplant therapies. *Biol Blood Marrow Transplant* 17(1 Suppl):S39-45, 1/2011. e-Pub 10/2010.
235. Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJ. Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study. *J Clin Oncol* 29(3):294-302, 1/2011. e-Pub 12/2010. PMID: PMC3056464.
236. Shpall EJ. The 2011 education supplement on hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 17(1 Suppl):S1, 1/2011. e-Pub 10/2010.
237. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. *Biol Blood Marrow Transplant* 17(3):412-20, 3/2011. e-Pub 7/2010.

238. Robinson SN, Simmons PJ, Yang H, Alousi AM, Marcos de Lima J, Shpall EJ. Mesenchymal stem cells in ex vivo cord blood expansion. *Best Pract Res Clin Haematol* 24(1):83-92, 3/2011. e-Pub 2/2011.
239. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. *Biol Blood Marrow Transplant* 17(6):893-900, 6/2011. e-Pub 10/2010.
240. Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O'Brien S, Fernandez-Viña M, Shpall EJ, Wierda WG. HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. *Leukemia* 25(6):1036-9, 6/2011. e-Pub 2/2011.
241. Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with Multiple Myeloma. *Cancer Res* 71(14):5040-9, 7/2011. e-Pub 6/2011.
242. Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattona A, Wei W, Sharma M, Anderlini P, Shpall EJ, Popat U, Rodrigues M, Champlin RE, de Lima M. Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission. *Biol Blood Marrow Transplant* 17(7):1067-71, 7/2011. e-Pub 11/2010.
243. Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, de Lima M, Shpall EJ, Champlin RE. Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell-Depleted Haploidentical Stem Cell Transplantation. *Biol Blood Marrow Transplant* 17(8):1169-75, 8/2011. e-Pub 11/2010.
244. Gonzalez G, Park S, Chen D, Armitage S, Shpall E, Behringer R. Identification and frequency of CCR5^{Δ32/Δ32} HIV-resistant cord blood units from Houston area hospitals. *HIV Med* 12(8):481-486, 9/2011. e-Pub 3/2011.
245. de Lima M, Fernandez-Vina M, Shpall EJ. HLA matching of CB: it's complicated. *Blood* 118(14):3761-2, 10/2011.
246. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinjima N, Shpall E, Huang X, Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 α -mediated down-regulation of CXCL12. *Blood* 118(16):4431-9, 10/2011. e-Pub 8/2011. PMID: PMC3204912.
247. Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO. Reversible Ureteral Obstruction due to Polyomavirus Infection after Percutaneous Nephrostomy Catheter Placement. *Biol Blood Marrow Transplant* 17(10):1551-5, 10/2011. e-Pub 3/2011.
248. Muralidharan S, Hanley PJ, Liu E, Chakraborty R, Bollard C, Shpall E, Rooney C, Savoldo B, Rodgers J, Dotti G. Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. *J Immunol* 187(10):5221-32, 11/2011. e-Pub 10/2011. PMID: PMC3208052.
249. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Mollidrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. *Blood* 118(22):5957-64, 11/2011. e-Pub 10/2011.
250. Raval M, Gulbis A, Bollard C, Leen A, Chemaly R, Shpall E, Lahoti A, Kebriaei P. Evaluation and Management of BK Virus-Associated Nephropathy following Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant* 17(11):1589-93, 11/2011. e-Pub 7/2011.
251. Perin EC, Tian M, Marini FC, Silva GV, Zheng Y, Baimbridge F, Quan X, Fernandes MR, Gahremanpour A, Young D, Paolillo V, Mukhopadhyay U, Borne AT, Uthamanthil R, Brammer D, Jackson J, Decker WK, Najjar AM, Thomas MW, Volgin A, Rabinovich B, Soghomonyan S, Jeong HJ, Rios JM, Steiner D, Robinson S, Mawlawi O, Pan T, Stafford J, Kundra V, Li C, Alauddin MM, Willerson JT, Shpall E, Gelovani JG. Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model. *PLoS One* 6(9):e22949, 2011. e-Pub 9/2011. PMID: PMC3164664.

252. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, Jordan CT, Kantarjian H, Wilson WR, Lock R, Andreeff M, Konopleva M. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. *PLoS One* 6(8):e23108, 2011. e-Pub 8/2011. PMID: PMC3154919.
253. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. *Adv Hematol* 2011:601953, 2011. e-Pub 11/2011. PMID: PMC3216266.
254. Nieto Y, Shpall EJ. High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later? *Biol Blood Marrow Transplant* 18(1):3-5, 1/2012. e-Pub 12/2011.
255. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory hodgkin lymphoma: preliminary results. *Leuk Lymphoma* 53(3):499-502, 3/2012. e-Pub 10/2011.
256. Kebriaei P, Saliba R, Rondon G, Chiattona A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. *Biol Blood Marrow Transplant* 18(4):584-92, 4/2012. e-Pub 8/2011.
257. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. *Leuk Lymphoma* 53(5):901-6, 5/2012. e-Pub 1/2012.
258. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. *Hum Gene Ther* 23(5):444-50, 5/2012. e-Pub 1/2012. PMID: PMC3360496.
259. Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PA. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R γ null (NSG) mice. *Exp Hematol* 40(6):445-56, 6/2012. e-Pub 2/2012. PMID: PMC3352960.
260. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, McQueen T, Pierce S, Shpall E, Konoplev S, Thomas D, Kantarjian H, Lock R, Andreeff M, Konopleva M. Regulation of HIF-1 α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. *Cancer Biol Ther* 13(10):858-70, 8/2012. e-Pub 8/2012. PMID: PMC3414410.
261. Lee DW, Futami M, Carroll M, Feng Y, Wang Z, Fernandez M, Whichard Z, Chen Y, Kornblau S, Shpall EJ, Bueso-Ramos CE, Corey SJ. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. *Oncogene* 31(37):4085-94, 9/2012. e-Pub 1/2012.
262. Pillai RN, Chen LS, Ayres ML, Nowak BJ, Thomas MW, Shpall EJ, Keating MJ, Gandhi V. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. *Leuk Lymphoma* 53(10):2024-32, 10/2012. e-Pub 4/2012.
263. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. *Biol Blood Marrow Transplant* 18(11):1677-86, 11/2012. e-Pub 5/2012.

264. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* 18(12):1819-26, 12/2012. e-Pub 6/2012.
265. Jelinek J, Liang S, Lu Y, He R, Ramagli LS, Shpall EJ, Estecio MR, Issa JP. Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. *Epigenetics* 7(12):1368-78, 12/2012. e-Pub 10/2012. PMID: PMC3528692.
266. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord Blood Engraftment With Ex-vivo Mesenchymal Cell Co- Culture. *N Engl J Med* 367(24):2305-15, 12/2012.
267. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T-cell Replete Graft Compared with T-cell Depleted Haploidentical Hematopoietic Stem-Cell Transplantation. *Biol Blood Marrow Transplant* 18(12):1835-44, 12/2012. e-Pub 7/2012.
268. Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH. Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation. *Biol Blood Marrow Transplant* 18(12):1851-8, 12/2012. e-Pub 7/2012. PMID: PMC3496817.
269. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsy J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. *Clin Cancer Res* 18(24):6758-70, 12/2012. e-Pub 10/2012. PMID: PMC3525747.
270. Ji Y, Feng L, Liu P, Shpall EJ, Kebriaei P, Champlin R, Berry D, Cooper LJ. Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. *J Biopharm Stat* 22(6):1206-19, 2012. PMID: PMC3501341.
271. Kebriaei P, Kelly SS, Manuri P, Jena B, Jackson R, Shpall E, Champlin R, Cooper LJ. Chimeric antibody receptors (CARs): Driving T-cell specificity to enhance anti-tumor immunity. *Front Biosci (Schol Ed)* 4:520-31, 2012. e-Pub 1/2012.
272. Hanley PJ, Lam S, Shpall EJ, Bollard CM. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. *J Vis Exp*(63):e3627, 2012. e-Pub 5/2012.
273. Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG. Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC. *PLoS One* 7(12):e51390, 2012. e-Pub 12/2012. PMID: PMC3526610.
274. Delaney C, Bollard CM, Shpall EJ. Cord Blood Graft Engineering. *Biol Blood Marrow Transplant* 19(1 Suppl):S74-8, 1/2013. e-Pub 10/2012.
275. Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N, Cutler C, Delaney C, Kan F, Isola L, Karanes C, Laughlin MJ, Wagner JE, Shpall EJ. Double Unit Grafts Successfully Extend the Application of Umbilical Cord Blood Transplantation in Adults with Acute Leukemia. *Blood* 121(5):752-8, 1/2013. e-Pub 12/2012. PMID: PMC3563363.
276. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. *Bone Marrow Transplant* 48(1):26-31, 1/2013. e-Pub 6/2012.

277. Bart T, Boo M, Balabanova S, Fischer Y, Nicoloso G, Foeken L, Oudshoorn M, Passweg J, Tichelli A, Kindler V, Kurtzberg J, Price T, Regan D, Shpall EJ, Schwabe R. Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations. *Transfus Med Hemother* 40(1):14-20, 2/2013. e-Pub 1/2013. PMID: PMC3635979.
278. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. *Biol Blood Marrow Transplant* 19(3):410-7, 3/2013. e-Pub 11/2012.
279. Hosing C, Kebriaei P, Wierda W, Jena B, Cooper LJ, Shpall E. CARs in Chronic Lymphocytic Leukemia - Ready to Drive. *Curr Hematol Malign Rep* 8(1):60-70, 3/2013. e-Pub 12/2012.
280. Petz LD, Redei I, Bryson Y, Regan D, Kurtzberg J, Shpall E, Gutman J, Querol S, Clark P, Tonai R, Santos S, Bravo A, Spellman S, Gragert L, Rossi J, Li S, Li H, Senitzer D, Zaia J, Rosenthal J, Forman S, Chow R. Hematopoietic Cell Transplantation with Cord Blood for Cure of HIV Infections. *Biol Blood Marrow Transplant* 19(3):393-7, 3/2013. e-Pub 10/2012.
281. Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. *Bone Marrow Transplant* 48(5):666-70, 5/2013. e-Pub 10/2012.
282. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. *Blood* 121(26):5113-23, 6/2013. e-Pub 4/2013. PMID: PMC3695359.
283. Battula VL, Chen Y, Cabreira Mda G, Ruvolo V, Wang Z, Ma W, Konoplev S, Shpall E, Lyons K, Strunk D, Bueso-Ramos C, Davis RE, Konopleva M, Andreeff M. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. *Blood* 122(3):357-66, 7/2013. e-Pub 6/2013. PMID: PMC3716201.
284. Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, Shpall EJ, Melenhorst JJ, Leen AM, Barrett AJ, Bollard CM. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. *Leukemia* 27(7):1538-47, 7/2013. e-Pub 3/2013.
285. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). *Biol Blood Marrow Transplant* 19(7):1059-64, 7/2013. e-Pub 4/2013.
286. de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K. Tyrosine kinase inhibitors impair B cell immune responses in CML through off-target inhibition of kinases important for cell signaling. *Blood* 122(2):227-38, 7/2013. e-Pub 5/2013.
287. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. *Biol Blood Marrow Transplant* 19(8):1227-32, 8/2013. e-Pub 5/2013.
288. Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MH. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. *Bone Marrow Transplant* 48(9):1218-23, 9/2013. e-Pub 3/2013.
289. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. *Biol Blood Marrow Transplant* 19(10):1453-8, 10/2013. e-Pub 7/2013.

290. Benjamini O, Jain P, Konoplev SN, Yin CC, Abruzzo L, Wotherspoon AC, Dearden C, Shpall EJ, Estrov Z, Keating MJ. CD4(-)/CD8(-) Variant of T-Cell Large Granular Lymphocytic Leukemia or Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Dilemma. *Clin Lymphoma Myeloma Leuk* 13(5):610-3, 10/2013. e-Pub 6/2013.
291. Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. *Ther Adv Hematol* 4(5):320-34, 10/2013. PMID: PMC3766348.
292. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirceted virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. *Blood* 122(17):2965-73, 10/2013. e-Pub 9/2013. PMID: PMC3811171.
293. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. *Clin Lymphoma Myeloma Leuk*. e-Pub 10/2013.
294. Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, Cardenas-Turanzas M, Price KJ, Champlin RE, Nates JL. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit. *J Clin Oncol* 31(33):4207-14, 11/2013. e-Pub 10/2013.
295. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. *J Clin Oncol*. e-Pub 12/2013.
296. Chakraborty S, Lin YH, Leng X, Miranda RN, Medeiros LJ, Shpall E, Arlinghaus RB. Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase. *Blood Cancer J* 3:e142, 2013. e-Pub 9/2013. PMID: PMC3789205.
297. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. *PLoS One* 8(10):e76781, 2013. e-Pub 10/2013.
298. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ. Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. *J Vis Exp*(72):e50070, 2013. e-Pub 2/2013. PMID: PMC3596954.
299. Oran B, Shpall EJ. Allele-level HLA cord blood matching matters. *Blood* 123(1):8-9, 1/2014.
300. Perissinotti AJ, Gulbis A, Shpall EJ, Howell J. Characterizing human herpes virus 6 following hematopoietic stem cell transplantation. *J Oncol Pharm Pract*. e-Pub 1/2014.
301. McNiece I, Shpall E. Does plerixafor destroy the hematopoietic progenitor cell/mesenchymal stromal cell niche? *Cytotherapy* 16(1):1-2, 1/2014.
302. Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Martín-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. *Cytotherapy* 16(1):84-9, 1/2014. e-Pub 10/2013. PMID: PMC3883688.
303. Parmar, S, Liu X, Tung S, Robinson S, Rodriguez G, Cooper L, Yang H, Shah, Yang H, Konopleva M, Molldrem J, Garcia-Manero, G, Najjar Amer, Yvon Eric, McNiece I, Rezvani K, Savoldo B, Bollard C, Shpall E. Third-party umbilical cord blood-derived regulatory T cells prevent. *Cytotherapy* 16(1):90-100, 1/2014.

Invited Articles

1. Demetri GD, Dale DC, Andrews RB, Shpall EJ, Brenner MK. Cytokines, Science and the Therapeutic Context: Current Practice, Controversies, and Future Applications . 2:12-5, 1994.

2. Shpall EJ. Peripheral Blood Progenitor Cell Harvesting. *Hematopoietic Therapy: Index & Reviews* 3(2), 1994.
3. Shpall EJ, Gee A, Cagnoni PJ, Hogan C, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB. Stem cell isolation. *Curr Opin Hematol* 2(6):452-9, 11/1995.
4. Shpall EJ, Cagnoni PJ, Bearman SI, Purdy MP, Jones RB. High-dose therapy with autologous hematopoietic support for the treatment of high-risk breast cancer. *ASCO Education Book. 31st Annual Meeting, May 20-23, 1995 Los Angeles, California:347-51, 1995.*
5. Auditore-Hargreaves K, Heimfeld S, Krieger M, Jacobs C, Shpall EJ, Berenson RJ. Selection and transplantation of hematopoietic stem cells. *Hematology Reviews* 9:73-83, 1995.
6. Warkentin PI, Nick L, Shpall EJ. FAHCT accreditation: common deficiencies during on-site inspections. *Cytotherapy* 2(3):213-20, 2000.
7. de Lima M Shpall EJ. Cord Blood Transplantation. *Curr Opin Organ Transplant* 7:186-293, 2002.
8. Naoto TUeno, Elizabeth JShpall, Richard EChamplin, Roy B, Jones. Graft-vs-Breast Cancer Effect by Allogeneic Hematopoietic Stem Cell Transplantation: A Possible New Frontier (in press). *Journal of Clinical Oncology*, 2004.

Editorials

1. Jones RB, Shpall EJ. Treatment of breast cancer in the 1990s. What does the future hold? *Drugs* 43(2):141-5, 2/1992.
2. Collins N, Gee A, Rowley S, Shpall E. Are we ready for regulation? ISHAGE Regulatory Action Group. *International Society for Hematotherapy and Graft Engineering. J Hematother* 4(1):1-2, 2/1995.
3. Suratt BT, Cool CD, Serls AE, Chen L, Varella-Garcia M, Shpall EJ, Brown KK, Worthen G. Cellular Alchem. *American Journal of Respiratory and Critical Care Medicine* 168:267-268, 2003.
4. Nieto Y, Jones RB, Shpall EJ. High-dose chemotherapy for breast cancer: is another look warranted? *Curr Opin Oncol* 16(2):114-9, 3/2004.
5. Ueno NT, Shpall EJ, Champlin RE, Jones RB. Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier. *J Clin Oncol* 22(19):3846-7, 10/2004.
6. Shpall E. de Lima Marcos, Jones Roy. Are two cords better than one? *Blood* 110:2789-2790, 10/2007.
7. Robinson S, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PA. Reply to Sackstein. *Exp Hematol* 7(40):519-20, 7/2012.

Other Articles

N/A

Abstracts (past 5 years)

1. Alousi Amin M, Rondon Gabriela, Okoroji, Grace-Julia, Popat Uday, De Padua Silva Leandro, Hymes, Sharon, Neumann Joyce, Brunelle Nicole M, Kebriaei Partow, Hosing Chitra, Khouri, Issa F, Shpall, Elizabeth J, Qazilbash, Muzaffar H, Giralt Sergio, Champlin Richard, and Saliba Rima M. Co-Morbidity Score at the Time of Transplant Determines Prognosis in Older Patients Who Develop Acute Graft-Vs.-Host Disease (GVHD). *Blood* 114(2244), 11/2009.
2. Hanley Patrick, Savoldo Barbara, Cruz, Conrad Russell Young, Leen Ann M., Jeffrey J. Molldrem, Liu Hao, Gee Adrian P., Heslop Helen E., Dotti Gianpietro, Rodgers John, Rooney, Cliona M ,Brenner Malcolm K., Shpall Elizabeth J., and Bollard.Catherine M. Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy. *Blood* 114(504), 11/2009.
3. Xing, Dongxia ,Ramsay Alan G., Decker William, Li Sufang, Robinson Simon, Yang Hong, Shah Nina, Hosing Chitra, Bollard Catherine M., Gribben John G., and Shpall Elizabeth J. Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2R null (NSG) Mice as a Model. *Blood* 114(2370), 11/2009.
4. Spencer Bryan P, Kaur Indreshpal, Fong Patrick, Karandish Safa, Ponweera Nirmali, Baez Omar, Shpall Elizabeth J, Champlin Richard E, and McMannis John D. Enrichment of Mononuclear Cells

- From Cryopreserved Cord Blood Units Using the Purecell" Select System. *Blood* 114(2159), 11/2009.
5. Xing Dongxia, Ramsay Alan G., Decker William, Li Sufang, Robinson Simon, Yang Hong, Bollard Catherine M., Gribben John G., and Shpall Elizabeth J. Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia. *Blood* 114(3029), 11/2009.
 6. Cruz Conrad Russell Y., Leen Ann M., Gerdemann Ulrike, Christin Anne S., Tripic Tamara, Shafer Jessica, Younes Anas, Horton Terzah M., Shpall, Elizabeth J., Heslop Helen E., Rooney, Cliona M. and Bollard Catherine M. Immune-Based Therapies Targeting Mage-A4 for Relapsed/Refractory Hodgkin's Lymphoma After Stem Cell Transplant. *Blood* 114(4089), 11/2009.
 7. Xing Dongxia, Ramsay Alan G., Decker William, Li Sufang, Robinson Simon, Yang Hong, Gribben John G., and Shpall Elizabeth J. Impaired Natural Killer Cells Immune Synapse Formation in Acute Myeloid Leukemia. *Blood* 114(2663), 11/2009.
 8. Kebriaei Partow, Madden Timothy, Kazerooni Reza, Shpall, Elizabeth, Wang Xuemei, Thall Peter, Hosing Chitra, Qazilbash Muzaffar, Popat Uday Ledesma, Celina, Khouri Issa, Champlin Richard, Jones Roy, and Andersson Borje S. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Non-Toxic Preparative Regimen for Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Lymphoid Malignancies. *Blood* 114(3415), 11/2009.
 9. de Lima Marcos, McMannis John D., Hosing Chitra, Kebriaei, Partow, Robinson Simon, Kelly Susan, de Padua Silva Leandro, Fernandez-Vina Marcelo, Chiattonne Alexandre, Bosque Doyle, Rondon Gabriela, Giralt Sergio, Cooper Laurence, Chen Julianne J, Parmar Simrit, Jones Roy, Andersson Borje, Worth Laura, AlousAmin i, McNiece Ian K., Komanduri Krishna V., Simmons Paul J, Champlin Richard E, and Shpall Elizabeth J. Rapid Engraftment of Neutrophils and Platelets with Mesenchymal Stem Cell Based Cord Blood (CB) Expansion (EXP). *Blood* 114(3394), 11/2009.
 10. Konopleva, Marina, Zhihong, Zeng, Wang, Rui-Yu, Thall, Peter F., McCormick, Gloria, Lu, Hongbo, Chen, Julianne J, Shpall, Elizabeth J., Ciurea, Stefan O., Kebriaei, Partow, Alousi, Amin M, Popat, Uday, Anderlini, Paolo, Nieto, Yago, Parmar, Simrit, McMullin, Becky, Rondon, Gabriela, Schober, Wendy D., Gulbis, Alison, Cool, Rita, E. Lin, Andreeff, Michael, and Champlin, Richard. A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogeneic Stem Cell Transplantation. *Blood* 116(2358), 11/2010.
 11. Shah, Nina, Xing, Dongxia, Lee, Dean A., Cooper, Laurence J.N., Decker, William, Li, Sufang, Robinson, Simon, Yang, Hong, Parmar, Simrit, Tung, Shawndeeep, Wang, Michael, Champlin, Richard, Bollard, Catherine M and Shpall, Elizabeth J. Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. *Blood* 116(2100), 11/2010.
 12. Kebriaei, Partow, Ledesma, Celina, Culotta, Kirk, Shpall, Elizabeth J., Ciurea, Stefan O., Alousi, Amin M, De Lima, Marcos, Popat, Uday, Thomas, Deborah A, Champlin, Richard E., and Andersson, Borje S. Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL). *Blood* 116(3484), 11/2010.
 13. Tang, XiaoWen, De Lima, Marcos, Wei, Wei, Chiattonne, Alexandre, Thall, Peter, Jeffrey, F. Medeiros, Rondon, Gabriela, Chen, Julianne J, Shpall, Elizabeth J., Jones, Roy, Nieto, Yago, Alousi, Amin M, Champlin, Richard E., and Andersson, Borje S. Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS. *Blood* 116(3446), 11/2010.
 14. Nieto, Yago, Anderlini, Paolo, Popat, Uday, Liu, Ping, Andersson, Borje S, Shpall, Elizabeth J., Kebriaei, Partow, Hosing, Chitra, Alousi, Amin M, Qazilbash, Muzaffar H., Ciurea, Stefan O. Parmar, Simrit, Champlin, Richard E., and Jones, Roy. Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel). *Blood* 116(690), 11/2010.

15. Ciurea, Stefan O., Mulanovich, Victor E., Jiang, Ying, Bassett, Roland, Rondon, Gabriela, McMannis, John, de Lima, Marcos, Shpall, Elizabeth J. and Champlin, Richard E. Lymphocyte Recovery Predicts Outcomes In Cord Blood and T-Cell Depleted Haploidentical Stem Cell Transplantation. *Blood* 116(2316), 11/2010.
16. Lima, Marcos De, Robinson Simon, McMannis John, Alousi Amin M, Saliba Rima M, Munsell Mark, Kebriaei, Partow, Hosing, Chitra, Parmar, Simrit, Cooper, Laurence, Shah, Nina, Staba Kelly, Susan, Rondon, Gabriela, Fernandez-Vina, Marcelo, Maewall, Ila, Bosque, Doyle, Bollard, Julianne Catherine, Chen M, J, McNiece, Ian K, Komanduri, Krishna V, Nieto, Yago, Jones, Roy, Andersson, Borje S, Papat, Uday, Champlin, Richard E., Simmons, Paul J., and Shpall Elizabeth J. Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. *Blood* 116(362), 11/2010.
17. Leen, Ann M., Bollard, Catherine M, Mendizabal, Adam M, Shpall Elizabeth J., Szabolcs, Paul, Antin, Joseph H., Kapoor, Neena, Heaton, Callie, Grilley, Bambi J, Gee, Adrian P., Brenner, Malcolm K., Rooney, Cliona M, and Heslop, Helen E. Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). *Blood* 116(829), 11/2010.
18. Kojima, Kensuke, McQueen, Teresa, Shpall, Elizabeth J., Wang, Rui-Yu and Andreeff, Michael. p53 Activation of Mesenchymal Stromal Cells (MSC) Partially Abrogates Microenvironment-Mediated Resistance to FLT3 Inhibition In FLT3/ITD AML. *Blood* 116(2151), 11/2010.
19. Alousi, Amin M, Andersson, Borje S., Saliba, Rima M., Botnick, Wendeline, Rondon, Gabriela, Shpall, Elizabeth J., de Lima, Marcos, Papat, Uday, Hosing, Chitra, Kebriaei Partow, Khouri, Issa, Qazilbash, Muzaffar H., Anderlini, Paolo, Nieto, Yago, Ciurea, Stefan, Jones, Roy, and Champlin, Richard. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. *Blood* 116(2341), 11/2010.
20. St. John, Lisa S, Clise-Dwyer, Karen, Patenia Rebecca, Sergeeva, Anna, Shpall, Elizabeth, Ma, J., Qing, and Molldrem, Jeffrey J. Surface Expression of PR1 Peptide on Thymic Dendritic Cells Does Not Eliminate PR1-Specific CD8+ Cells In Umbilical Cord Blood. *Blood* 116(959), 11/2010.
21. Benito, Juliana, Yuexi Shi, Szymanska, Barbara, Carol, Hernan, Bohem, Ingrid, Lu, Hongbo, Konoplev, Sergej, Fang, Wendy, Kornblau, Steven M., Zweidler-McKay, Patrick, Wilson, William, Campana, Dario, Borthakur, Gautam, Bueso-Ramos, Carlos E., Kantarjian, Hagop M., Shpall, Elizabeth J., Thomas, Deborah A, Jordan, Craig T., Lock, Richard B, Andreeff, Michael, and Konopleva, Marina. Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104. *Blood* 116(868), 11/2010.
22. Tung, Shawndee, Decker, William, Robinson, Simon, Shah, Nina, Klumpp, Stephens Clifton, Sherry, Konopleva, Marina, Garcia-Manero, Guillermo, Cooper, Laurence, Shpall Elizabeth J., and Parmar, Simrit. Third Party Umbilical Cord Blood Regulatory T Cells Prevents Graft Versus Host Disease In a Xenogenic Murine Model. *Blood* 116(3737), 11/2010.
23. Champlin, Richard, Lee, Dean A., Fernandez- Vina, Marcelo, Rondon, Gabriela, McAdams, Patricia, Julianne, Chen, Qazilbash, Muzaffar H., Kebriaei, Partow, Parmar, Simrit, Shpall, Elizabeth J., Papat, Uday, Alousi, Amin, Ciurea, Stefan O., Cooper, Laurence, Peter, Thall and McMannis, John. Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. *Blood* 116(489), 2010.
24. Ciurea, Stefan O., Aung, Fleur, de Lima, Marcos, Thall, Peter F., Rondon, Gabriela, Kebriaei Partow, Alousi, Amin, Shpall, Elizabeth J., Hosing, Chitra, Khouri, Issa F, Champlin, Richard E., and Fernandez-Vina, Marcelo. Anti-HLA Antibodies and Graft Rejection In Hematopoietic Stem Cell Transplantation. *Blood* 116(519), 2010.
25. Shah, Nina, Decker, William, Lapushin, Ruth, Xing, Dongxia, Robinson, Simon, Yang, Hong, Parmar, Simrit, Tung, Shawndee, O'Brien, Susan, Fernandez-Vina, Marcelo, Shpall, Elizabeth J., and Wierda, William G. HLA Homozygosity and Haplotype Bias Among Patients with Chronic Lymphocytic Leukemia: Implications for Disease Control by Physiologic Immune Surveillance. *Blood* 116(1370), 2010.
26. Ang, Sonny, Da Silva, Maria Lima, Dawson, Margaret, Figliola, Matthew, Maiti, Sourindra, Huls, Helen, Shpall, Elizabeth J., Champlin, Richard, Lee, Dean A., Silla, Lucia, and Cooper, Laurence

- J.N. NK Cell Proliferation and Cytolytic Function Are Compromised In the Hypoxic Tumor Microenvironment. *Blood* 116(4291), 2010.
27. Xing ,Dongxia, Decker, William, Li, Sufang, Robinson, Simon, Shah, Nina, Yang, Hong, Champlin, Richard E., Parmar, Simrit, Gribben, John G., Bollard, Catherine M, and Shpall, Elizabeth. Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. *Blood* 116(2453), 2010.
 28. Schuster, S. J., Hosing, C. M., Shpall, E. J., Levine, B. L., Aqui, N. A., Chong, E. A., Svoboda, J., Gordon, A., McMannis, J. D., Bosque, D., Cotte, J., Brennan, A. L., Zheng, Z., Leinbach, L., Xu, Y., Veloso, E., Decker, W., Bollard, C. M., Keating, M. J. & June, C. H. Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. *Blood* (ASH Annual Meeting Abstract) 118(2855), 2011.
 29. Popat, U., Andersson, B. S., Bassett, R., Ciurea, S., Rondon, G., Alousi, A. M., Anderlini, P., Hosing, C., Jones, R., Kebriaei, P., Nieto, Y., Khouri, I., Shpall, E. J., Verstovsek, S., Qazilbash, M., de Lima, M. J. & Champlin, R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. *Blood* (ASH Annual Meeting Abstract) 118(2006), 2011.
 30. Xing, D., Ramsay, A. G., Decker, W., Lee, D. A., Robinson, S., Shah, N., Parmar, S., Bollard, C. M., Hosing, C. M., Champlin, R., Gribben, J. G. & Shpall, E. J. CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. *Blood* (ASH Annual Meeting Abstract) 118(246), 2011.
 31. Anderlini, P., Saliba, R. M., Ledesma, C., Chancoco, C. M., Acholonu, S., Valverde, R., Popat, U. R., Hosing, C. M., Alousi, A. M., Shpall, E. J., Nieto, Y., Ciurea, S. O., Khouri, I. & Champlin, R. Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL). *Blood* (ASH Annual Meeting Abstract) 118(3003), 2011.
 32. Bayraktar, U. D., Shpall, E. J., Liu, P., Ciurea, S. O., De Lima, M., Rondon, G., Price, K. J., Champlin, R. & Nates, J. L. Hematopoietic Cell Transplantation - Specific Comorbidity Index As An Instrument to Predict Survival in Patients Admitted to Intensive Care Unit Early After Allogeneic Transplantation. *Blood* (ASH Annual Meeting Abstract) 118(147), 2011.
 33. Nieto, Y., Thall, P. F., Andersson, B. S., Popat, U. R., Anderlini, P., Valdez, B. C., Shpall, E. J., Qazilbash, M., Alousi, A. M., Chancoco, C., Hosing, C. M., Kebriaei, P., Bashir, Q., Shah, N., Khouri, I., Ciurea, S. O., McMullin, B., Rondon, G., Champlin, R. & Jones, R. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. *Blood* (ASH Annual Meeting Abstract) 118(3083), 2011.
 34. Ciurea, S. O., Saliba, R. M., Bayraktar, U. D., Xie, S., Rondon, G., Parmar, S., Kebriaei, P., Montes, N., Sharma, M., Konopleva, M., Nieto, Y., Qazilbash, M. H., Alousi, A. M., Andersson, B. S., Hosing, C. M., Shpall, E. J., Khouri, I. F., de Lima, M. & Champlin, R. Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT). *Blood* (ASH Annual Meeting Abstract) 118(320), 2011.
 35. Cruz, C. R. Y., Micklethwaite, K. P., Savoldo, B., Ku, S., Krance, R. A., Diouf, O., Kamble, R., Barrett, A. J., Shpall, E. J., Heslop, H. E., Rooney, C. M., Brenner, M. K., Bollard, C. M. & Dotti, G. Infusion of CD19-Directed and Multivirus Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation for B Cell Malignancies. *Blood* (ASH Annual Meeting Abstract) 118(4083), 2011.
 36. Xing, D., Ramsay, A. G., Robinson, S., Bollard, C. M., Shah, N., Champlin, R., Gribben, J. G. & Shpall, E. J. Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. *Blood* (ASH Annual Meeting Abstract) 118(1794), 2011.
 37. Popat, U., Bassett, R., de Padua Silva, L., Alousi, A. M., Anderlini, P., Hosing, C. M., Jones, R., Kebriaei, P., Khouri, I., Shpall, E. J., Qazilbash, M. H., Garcia-Manero, G., Andersson, B. S., Champlin, R. & de Lima, M. J. Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. *Blood* (ASH Annual Meeting Abstract) 118(4531), 2011.

38. Popat, U., Bassett, R., de Padua Silva, L., Alousi, A. M., Anderlini, P., Hosing, C. M., Jones, R., Kebriaei, P., Khouri, I., Shpall, E. J., Qazilbash, M. H., Garcia-Manero, G., Andersson, B. S., Champlin, R. & de Lima, M. J. Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. *Blood (ASH Annual Meeting Abstract)* 118(4531), 2011.
39. Hanley, P. J., Melenhorst, J. J., Scheinberg, P., Demmler-Harrison, G. J., Lilleri, D., Gerna, G., Heslop, H. E., Rooney, C. M., Barrett, A. J., Shpall, E. J. & Bollard, C. M. Naive T Cell-Derived CTL Recognize Atypical Epitopes of CMVpp65 with Higher Avidity Than CMV-Seropositive Donor-Derived CTL - a Basis for Treatment of Post-Transplant Viral Infection by Adoptive Transfer of T Cells From Virus-naive Donors. *Blood (ASH Annual Meeting Abstract)* 118(3002), 2011.
40. Hanley, P. J., Melenhorst, J. J., Scheinberg, P., Demmler-Harrison, G. J., Lilleri, D., Gerna, G., Heslop, H. E., Rooney, C. M., Barrett, A. J., Shpall, E. J. & Bollard, C. M. Naive T Cell-Derived CTL Recognize Atypical Epitopes of CMVpp65 with Higher Avidity Than CMV-Seropositive Donor-Derived CTL - a Basis for Treatment of Post-Transplant Viral Infection by Adoptive Transfer of T Cells From Virus-naive Donors. *Blood (ASH Annual Meeting Abstract)* 118(3002), 2011.
41. Andersson, B. S., de Lima, M. J., Saliba, R. M., Shpall, E. J., Popat, U., Jones, R., Nieto, Y., Hosing, C. M., Kebriaei, P., Alousi, A. M., Worth, L. L., Madden, T., Gulbis, A., Chen, J. J., Rondon, G., McAdams, P., McMullin, B., Andreeff, M. & Champlin, R. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS; Results of a Randomized Phase III Study. *Blood (ASH Annual Meeting Abstract)* 118(892), 2011.
42. Hanley, P. J., Martinez, C., Leung, K., Savaldo, B., Dotti, G., Gee, A. P., Rooney, C. M., Heslop, H. E., Krance, R. A., Shpall, E. J. & Bollard, C. M. Phase I Study to Improve Virus-Specific Immune Reconstitution After Cord Blood Transplantation Using Cord Blood-Derived Virus-Specific Cytotoxic T Lymphocytes. *Blood (ASH Annual Meeting Abstract)* 118(155), 2011.
43. Saliba, R. M., Chiattonne, A., Majlis, A., Chiattonne, V. C., Rondon, G., Sakashita, A. M., Hamerschlak, N., Kutner, J. M., Shpall, E. J., Anderlini, P., Khouri, I., Qazilbash, M. H., Popat, U., Champlin, R., Hosing, C. M. & De Lima, M. Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization. *Blood (ASH Annual Meeting Abstract)* 118(4058), 2011.
44. Saliba, R. M., Chiattonne, A., Majlis, A., Chiattonne, V. C., Rondon, G., Sakashita, A. M., Hamerschlak, N., Kutner, J. M., Shpall, E. J., Anderlini, P., Khouri, I., Qazilbash, M. H., Popat, U., Champlin, R., Hosing, C. M. & De Lima, M. Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization. *Blood (ASH Annual Meeting Abstract)* 118(4058), 2011.
45. Zhou, Y., Jorgensen, J. L., Saliba, R. M., Wang, S. A., Rondon, G., Ledesma, C., Andersson, B. S., de Lima, M. J., Shpall, E. J., Popat, U., Ciurea, S. O., Alousi, A. M., Qazilbash, M., Hosing, C. M., Medeiros, L. J., Champlin, R. & Kebriaei, P. Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation. *Blood (ASH Annual Meeting Abstract)* 118(3072), 2011.
46. Lima, M. D., Ahmed, S., Shpall, E. J., Rondon, G., Chen, J., Woodworth, G. G., Chiattonne, A., Chu, D. T., Popat, U. R., Campos, S. R., Alousi, A. M., Hosing, C. M., Parmar, S., Kebriaei, P., Khouri, I. F., Cortes, J. E., Issa, J.-P. J. & Champlin, R. Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. *Blood (ASH Annual Meeting Abstract)* 118(3106), 2011.
47. Sergeeva, A., He, H., Ruisaard, K., Clise-Dwyer, K., St. John, L. S., Patenia, R., Sukhumalchandra, P., Alatrash, G., Decker, W. K., Shpall, E. J., You, M. J., Ma, Q. & Molldrem, J. J. Treatment with 8F4, An Anti-PR1/HLA-A2 T Cell Receptor-Like Antibody, Reduces Established Acute Myeloid Leukemia and Eliminates Leukemia Stem Cells in Mice. *Blood (ASH Annual Meeting Abstract)* 118(766), 2011.
48. Gul, Z., Bashir, Q., Nieto, Y., Sherwani, N., Parmar, S., Shah, N., Dinh, Y. T., Hosing, C. M., Popat, U. R., Kebriaei, P., Shpall, E. J., Giral, S. A., Champlin, R. E. & Qazilbash, M. H. Cardiac

- Toxicity After High-Dose Melphalan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. *Blood (ASH Annual Meeting Abstract)* 120(2027), 11/2012.
49. Conter, H. J., Nguyen, N.-N., Rondon, G., Chen, J., Shpall, E. J., Khouri, I., Giralto, S. A., Champlin, R. E. & DeLima, M. Comorbidity and Outcomes for Patients Over Age 65 Years Treated with Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. *Blood (ASH Annual Meeting Abstract)* 120(2032), 11/2012.
 50. Gul, Z., Khan, H., Bashir, Q., Shah, N., Parmar, S., Dinh, Y. T., Hosing, C. M., Popat, U. R., Kebriaei, P., Anderlini, P., Shpall, E. J., Giralto, S., Champlin, R. E. & Qazilbash, M. H. EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma. *Blood (ASH Annual Meeting Abstract)* 120(3094), 11/2012.
 51. Hanley, P. J., Martinez, C., Leung, K., Savoldo, B., Dotti, G., Brenner, M. K., Rooney, C. M., Heslop, H. E., Krance, R. A., Shpall, E. J. & Bollard, C. M. Improving Immune Reconstitution After Cord Blood Transplantation Using Ex Vivo Expanded Virus-Specific T Cells: A Phase I Clinical Study. *Blood (ASH Annual Meeting Abstract)* 120(224), 11/2012.
 52. Benton, C. B., Konopleva, M., Saliba, R. M., Shpall, E. J., Ciurea, S. O., Kebriaei, P., Alousi, A. M., Popat, U. R., Anderlini, P., Nieto, Y., Parmar, S., Zeng, Z., Chen, J. J., Rondon, G., McMullin, B., Wang, R.-Y., Lu, H., Schober, W. D., Woodworth, G. G., Gulbis, A., Cool, R., Qiao, W., Thall, P. F., Andreeff, M. & Champlin, R. E. Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse. *Blood (ASH Annual Meeting Abstract)* 120(360), 11/2012.
 53. de Lima, M., Parmar, S., Chen, J. J., Giralto, S. A., Rondon, G., Popat, U. R., Alousi, A. M., Lee, H. C., Woodworth, G. G., Hosing, C. M., Shpall, E. J., Kebriaei, P., Manero, G. g., Champlin, R. E. & Saliba, R. M. Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). *Blood (ASH Annual Meeting Abstract)* 120(742), 11/2012.
 54. Hamdi, A., Poon, L. M., Saliba, R. M., Rondon, G., Ledesma, C., Qazilbash, M., Hosing, C. M., Jones, R. B., Popat, U. R., Nieto, Alousi, A. M., Ciurea, S. O., Shpall, E. J., Champlin, R. E. & Kebriaei, P. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). *Blood (ASH Annual Meeting Abstract)* 120(4215), 11/2012.
 55. Di Stasi, A., Poon, M., Hamdi, A., Shaim, H., Xie, S., Milton, D., Bassett, R., Rondon, G., Shpall, E. J., Cooper, L., Lee, D., Rezvani, K., Champlin, R. E. & Ciurea, S. O. Reconstitution of Lymphocyte Subsets and Outcomes After Matched and Mismatched Hematopoietic Stem-Cell Transplantation. *Blood (ASH Annual Meeting Abstract)* 120(4485), 11/2012.
 56. Ahmed, S., Saliba, R. M., De Lima, M., Rondon, G., Kebriaei, P., Fisher, T. D., Jabbour, E., Chen, J., Kantarjian, H., Anderlini, P., Alousi, A. M., Hosing, C. M., Andersson, B., Jones, R. B., Qazilbash, M. H., Shpall, E. J., Giralto, S. & Champlin, R. E. Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia. *Blood (ASH Annual Meeting Abstract)* 120(3129), 11/2012.
 57. Alousi, A. M., Saliba, R. M., Chen, J., Andersson, B. S., Khouri, I., Qazilbash, M. H., Popat, U. R., Hosing, C. M., Ciurea, S. O., Shpall, E. J., Jones, R. B., Kebriaei, P., Nieto, Y., Anderlini, P., DeLima, M., Rondon, G. & Champlin, R. E. Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. *Blood (ASH Annual Meeting Abstract)* 120(4200), 2012.
 58. Huls, H., Singh, H., Olivares, S., Figliola, M., Kumar, P. R., Jena, B., Jackson, R. N., Liu, T., McNiece, I. K., Rondon, G., Hackett, P., Champlin, R. E., Shpall, E. J. & Cooper, L. J. N. Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor. *Blood (ASH Annual Meeting Abstract)* 12(4208), 2013.
 59. Hosing, C. M., Shpall, E. J., Levine, B. L., Aqui, N. A., Chong, E. A., Svoboda, J., Bosque, D., Cotte, J., Zheng, Z., Kaur, I., Veloso, E., Bollard, C. M., Keating, M. J. & June, C. H. Adoptive Immunotherapy With Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based

- Chemotherapy In Patients With Chronic Lymphocytic Leukemia. *Blood (ASH Annual Meeting Abstract)* 122(2874), 2013.
60. Khoder, A., Alsuliman, A., Chew, C., Sekine, T., Cooper, N., de Lavallade, H., Muftuoglu, M., Yvon, E., Hamdi, A., Alousi, A., John, L. S. S., Marin, D., Stringaris, K., Liu, E., Molldrem, J. J., Shah, N., Parmar, S., McNiece, I. K., Champlin, R. E., Shpall, E. J. & Rezvani, K. B Cell With Regulatory Function Are Enriched Within Transitional and IgM Memory B Cell Subsets In Healthy Donors But Are Reduced and Functionally Impaired In Patients With Chronic Graft-Versus-Host Disease. *Blood (ASH Annual Meeting Abstract)* 122(4478), 2013.
 61. Benito, J. M., Somanchi, A., Duvvuri, S., Hodgson, L., Chen, Y., Ma, W., Davis, R. E., McNiece, I. K., Shpall, E. J., Konopleva, M. & Andreeff, M. Bone Marrow Microenvironment Induces Stem Cell-Like Phenotype In Acute Myeloid Leukemia. *Blood (ASH Annual Meeting Abstract)* 122(2457), 2013.
 62. Alsuliman, A., Khoder, A., Ahn, Y.-O., Liu, E., Chew, C., Hamdi, A., Sekine, T., Sarvaria, A., Cooper, N., de Lavallade, H., Marin, D., Stringaris, K., Verneris, M. R., Shpall, E. J. & Rezvani, K. CD161 Expression Identifies a Distinct Subset Of Drug-Effluxing Viral-Specific Memory CD4+ T Cells That Preferentially Survive Cytotoxic Chemotherapy. *Blood (ASH Annual Meeting Abstract)* 122(2024), 2013.
 63. Poon, M., Chen, J., Rondon, G., Ahmed, S., Andersson, B. S., Bashir, Q., Ciurea, S. O., Hosing, C. M., Parmar, S., Qazilbash, M. H., Popat, U. R., Nieto, Y., Alousi, A., Jones, R. B., Rezvani, K., de Lima, M., Shpall, E. J., Champlin, R. E. & Kebriaei, P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). *Blood (ASH Annual Meeting Abstract)* 122(2142), 2013.
 64. Robinson, S. N., Thomas, M. W., Lu, J., Yang, H., Champlin, R. E., Schober, W. D., Simmons, P. J. & Shpall, E. J. Cord Blood CD34+ Stem Cell Sialyl Lewis X Levels and E-Selectin Binding Are Predictive Of Engraftment In Mice: Functional Separation Of Stemness and Homing To Improve Engraftment. *Blood (ASH Annual Meeting Abstract)* 122(893), 2013.
 65. Di Stasi, A., Shpall, E. J., Khouri, I. F., Alousi, A. M., Ciurea, S. O., Bashir, Q., Qazilbash, M., Jones, R. B., Nieto, Y., Parmar, S., Kebriaei, P., Shah, N., Rezvani, K., Hosing, C. M., Oran, B., Andreeff, M., Anderlini, P., Andersson, B. S., Champlin, R. E. & Popat, U. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. *Blood (ASH Annual Meeting Abstract)* 122(2083), 2013.
 66. Oran, B., Hosing, C. M., Kebriaei, P., Rezvani, K., Parmar, S., Shah, N., Bollard, C. M., Molldrem, J. J., Nieto, Y., Andersson, B. S., Alousi, A., Jones, R. B., Cooper, L. J. N., Qazilbash, M. H., Bashir, Q., Ahmed, S., Bosque, D., Chen, J., McCarty, J., Rondon, G., Munsell, M., McNiece, I. K., Kaur, I., Yvon, E., Annandale, K., Olchesky, S., de Lima, M. J., Champlin, R. E., Miller, L., Paradiso, L., Koh, L., Zweidler-McKay, P. A. & Shpall, E. J. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. *Blood (ASH Annual Meeting Abstract)* 122(691), 2013.
 67. Huls, H., Singh, H., Olivares, S., Figliola, M., Kumar, P. R., Jena, B., Forget, M. A., Ang, S., Jackson, R. N., Liu, T., Bosque, D., McNiece, I. K., Rondon, G., Hackett, P., Hosing, C. M., Shpall, E. J., Champlin, R. E. & Cooper, L. J. N. First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. *Blood (ASH Annual Meeting Abstract)* 122(166), 2013.
 68. Xiaoying, L., Tung, S., Setoyama, T., D'Abundo, L., Simon, R., Yang, H., Yvon, E., Shah, N., Yang, H., Garcia-Manero, G., McNiece, I. K., Rezvani, K., Calin, G. & Shpall, E. J. FOXP3 Is a Direct Target Of miR15a/16 in Umbilical Cord Blood Regulatory T Cells. *Blood* 122(3261), 2013.
 69. Denai, M., Di Stasi, A., Kebriaei, P., Popat, U. R., Alousi, A., Anderlini, P., Parmar, S., Hosing, C. M., Andersson, B. S., Bashir, Q., Ahmed, S., Oran, B., Shpall, E. J., Khouri, I., Konopleva, M., Alatrash, G., Champlin, R. E. & Ciurea, S. O. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. *Blood (ASH Annual Meeting Abstract)* 122(4523), 2013.
 70. Li, S., Coughlin, E., Breault, E., Liney, D., Kao, G., Snow, K., Haspel, R. L., Kurtzberg, J., Scaradavou, A., Shpall, E. J., Glotzbecker, B., Armand, P., Koreth, J., Ho, V. T., Alyea, E. P., Ritz, J., Soiffer, R. J., Antin, J. H., Dey, B. R., McAfee, S., Chen, Y.-B., Spitzer, T. R., Avigan, D.,

- Cutler, C. S. & Ballen, K. K. Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. *Blood* (ASH Annual Meeting Abstract) 122(695), 2013.
71. Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A. J., Ito, S., Shpall, E. J., Krance, R. A., Kamble, R. T., Carrum, G., Hosing, C. M., Gee, A. P., Mei, Z., Grilley, B. J., Heslop, H. E., Rooney, C. M., Brenner, M. K., Bollard, C. M. & Dotti, G. Infusion Of Donor-Derived CD19-Redirected-Virus-Specific T Cells For B-Cell Malignancies Relapsed After Allogeneic Stem Cell Transplant: A Phase I Study. *Blood* (ASH Annual Meeting Abstract) 122(152), 2013.
 72. de Lima, M. J., Lee, D. A., Worth, L., Kongtim, P., Petropoulos, D., McNiece, I. K., Shpall, E. J., Rondon, G. & Champlin, R. E. Is There An Expiration Date For Cord Blood Units In Storage? *Blood* (ASH Annual Meeting Abstract) 122(299), 2013.
 73. Popat, U. R., de Lima, M., Garcia-Manero, G., Jabbour, E. J., Chen, J., Rondon, G., Abruzzo, L. V., Ciurea, S. O., Shpall, E. J., Champlin, R. E. & Oran, B. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. *Blood* (ASH Annual Meeting Abstract) 122(3340), 2013.
 74. Najjar, A., Robinson, S. N., Chew, C., Sufang, L., Yvon, E., Thomas, M. W., Rezvani, K., Shpall, E. J. & Shah, N. NK Cells Kill Myeloma Cells By Increasing ER Stress and Decreasing Autophagy Levels. NKG2D and NKP30 Are Involved In These Processes. *Blood* (ASH Annual Meeting Abstract) 122(3487), 2013.
 75. Rozovski, U., Jain, P., Wierda, W. G., O'Brien, S., Burger, J. A., Ferrajoli, A., Faderl, S. H., Shpall, E. J., Hosing, C. M., Khouri, I. F., Champlin, R. E., Keating, M. J. & Estrov, Z. Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation. *Blood* (ASH Annual Meeting Abstract) 122(2880), 2013.
 76. Wang, R.-y., Ruvolo, V. R., Jacamo, R., McQueen, T., Borthakur, G., Qiu, Y., Coombes, K. R., Zhang, N., Shpall, E. J., Champlin, R. E., Garzon, R., Marcucci, G., Croce, C. M., Konopleva, M., Andreeff, M. & Kornblau, S. M. Phosphorylation Of GSK3 β Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. *Blood* (ASH Annual Meeting Abstract) 122(2551), 2013.
 77. John, L, He H, Ruisaard K, Ma, Q, Shpall, E, Moll dre, J. PR1-CTL directly sort-purified from umbilical cord blood lymphocytes reduce human AML in vivo. *J Immunology* 190(177), 2013.
 78. Kongtim, P., de Lima, M., Popat, U. R., Garcia-Manero, G., Jabbour, E. J., Abruzzo, L. V., Chen, J., Rondon, G., Andersson, B. S., Alousi, A., Ciurea, S. O., Shpall, E. J. & Champlin, R. E. Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. *Blood* (ASH Annual Meeting Abstract) 122(305), 2013.
 79. Lichtiger, B., Alousi, A., Ahmed, S., Anderlini, P., Andersson, B. S., Bashir, Q., Ciurea, S. O., Jones, R. B., Kebriaei, P., Nieto, Y., Oran, B., Parmar, S., Qazilbash, M. H., Shah, N., Khouri, I., Shpall, E. J., Champlin, R. E. & Popat, U. R. Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia. *Blood* (ASH Annual Meeting Abstract) 122(5449), 2013.
 80. Saliba, R. M., Ledesma, C., Chancoco, C. M., Alexander, T., Alousi, A., Hosing, C. M., Khouri, I., Nieto, Y., Popat, U. R., Shpall, E. J., Fanale, M. A., Oki, Y., Romaguera, J. E., Neelapu, S., Younes, A. & Champlin, R. E. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). *Blood* (ASH Annual Meeting Abstract) 122(410), 2013.
 81. Garrido-Laguna, I., Velez-Bravo, V., Falchook, G. S., Subbiah, V., Hong, D. S., Oki, Y., Westin, J. R., Nunez, C. A., Fayad, L. E., Kwak, L. W., Shpall, E. J., Wheler, J. J., Liang, W., Salhia, B., Meric-Bernstam, F., Kurzrock, R. & Fanale, M. Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. *Blood* (ASH Annual Meeting Abstract) 122(3048), 2013.
 82. Hamdi, A., Kongtim, P., Milton, D., Alousi, A., Anderlini, P., Ciurea, S. O., Oran, B., Khouri, I., Parmar, S., Qazilbash, M. H., Kebriaei, P., Popat, U. R., Rezvani, K., Chemaly, R. F., Shpall, E. J., Champlin, R. E. & Bashir, Q. The Effect Of CMV Reactivation On Relapse and Survival In

- Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). *Blood* (ASH Annual Meeting Abstract) 122(4531), 2013.
83. Poon, L. M., Ferro, R., Milton, D., Rondon, G., Wang, S. A., Hamdi, A., Qazilbash, M. H., Ahmed, S., Khouri, I., Oran, B., Hosing, C. M., Kebriaei, P., Alousi, A., Popat, U. R., Shpall, E. J., Lee, D. A., Rezvani, K., Champlin, R. E. & Ciurea, S. O. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. *Blood* (ASH Annual Meeting Abstract) 122(2167), 2013.
 84. Thall, P. F., Valdez, B. C., Hosing, C. M., Ahmed, S., Jones, R. B., Shah, N., Anderlini, P., Qazilbash, M. H., Popat, U. R., Bashir, Q., Shpall, E. J., Alousi, A., Kebriaei, P., Fox, P., Bassett, R., Chancoco, C., Oki, Y., Fanale, M. A., Fowler, N., Hagemester, F., Romaguera, J. E., Champlin, R. E. & Andersson, B. S. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. *Blood* (ASH Annual Meeting Abstract) 122(2095), 2013.
 85. Blood. Xiaoying, L., Tung, S., Setoyama, T., D'Abundo, L., Simon, R., Yang, H., Yvon, E., Shah, N., Yang, H., Garcia-Manero, G., McNiece, I. K., Rezvani, K., Calin, G. & Shpall, E. J. FOXP3 Is a Direct Target Of miR15a/16 in Umbilical Cord Blood Regulatory T Cells. 122(3261), 2013.
 86. Mi, T., Ang, S. O., Gragert, L., Maiers, M., Maiti, S., Switzer, K., Huls, H., Reik, A., Holmes, M. C., Gregory, P. D., Champlin, R. E., Shpall, E. J. & Cooper, L. J. N. ZFN-Driven Gene Editing Prevents HLA-A Expression On Hematopoietic Stem Cells -Improving The Chance Of Finding An HLA-Matched Donor. *Blood* 122(1655), 2013.

Book Chapters

1. Peters WP, Shpall EJ, Jones RB, Olsen G, Gockerman J, Eder JP, Antman K, Kurtzberg J, Bast RC, Moore JO, Egorin MJ. Critical factors in the design of high-dose combination chemotherapy regimens. In: *Advances in Cancer Chemotherapy: Symposium on High-Dose Thiotepa and Autologous Transplantation*. Park Row, 43-52, 1987.
2. Peters WP, Jones RB, Shpall EJ, Gockerman J, Kurtzberg J, Moore J, Bast RC, Gilbert C, Blackburn B, Coniglio D, Brophy L, Edwards S. Strategies in the treatment of breast cancer with intensive chemotherapy and autologous bone marrow support. In: *Autologous Bone Marrow Transplantation*. 1. Proceedings of the Second International Symposium Cancer Treatment Research Education Fund, Arlington, Texas, 657-67, 1987.
3. Shpall EJ, Jones RB, Bast R, Shogan J, Ross M, Edwards S, Eggleston S, Johnston C, Affronti M, Coniglio D, Peters WP. 4-hydroperoxycyclophosphamide (4-HC) purging of the ficolled mononuclear cell fraction (FMNCF) of bone marrow. In: *Proc of the 2nd International Symposium on Bone Marrow Processing and Purging*. Wiley-Liss, 1989.
4. Peters WP, Atwater S, Kurtzberg J, Borowitz M, Brandt SJ, Coleman RE, Kim CS, Gilbert C, Shpall EJ, Jones RB, Shogan J, Bast RC, Oette D, Stuart A, Coniglio D, Affronti ML, Evans S. The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. In: *Autologous Bone Marrow Transplantation*. 4. Proc. of the Fourth International Symposium Cancer Treatment Research Education Fund, Arlington, Texas, 657-67, 1989.
5. Shpall EJ, Anderson IC, Bast, JrR, Joines W, Jones RB, Ross M, Edwards S, Eggleston S, Johnston C, Tepperberg M, Affronti ML, Coniglio D, Mathias B, Peters W. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. In: *Bone Marrow Purging and Processing*. Wiley-Liss Inc., 321-36, 1990.
6. Shpall EJ, Bast RC, Johnston CS, Peters WP, Jones RB. Combined purging approaches in autologous transplantation. In: *Bone Marrow Processing and Purging: A Practical Guide*. CRC Press, 307-28, 1991.
7. Shpall EJ, Jones RB, Bast RC, Johnston CS, Ross M, Anderson I, Peters WP: Immunopharmacologic purging of breast cancer from bone marrow. Immunopharmacologic purging of breast cancer from bone marrow. In: *Autologous Bone Marrow Transplantation: Proceedings of the Fifth International Symposium Cancer Treatment Research Education Fund*. 5, 379-84, 1991.

8. Shpall EJ, Bast RC, Johnston CS, Peters WP, Jones RB. Immunopharmacologic purging of breast cancer from bone marrow. In: *Breast Epithelial Antigens: Molecular Biology to Clinical Applications*. Plenum Press, 211-14, 1991.
9. Shpall EJ, Johnston C, Hami L. Bone Marrow Purging. In: *High-Dose Therapy: Pharmacology, Hematopoietins, and Stem Cells*. Williams and Wilkins, 249-75, 1992.
10. Stiff P, Antman K, Broun R, Collins R, Fields K, Kessinger A, Shea T, Shpall E, Spitzer G. Bone marrow transplantation for ovarian carcinoma in the United States: A survey of active programs. In: *Autologous Bone Marrow Transplantation*. 6. Proceedings of the Sixth International Symposium Cancer Treatment Research Education Fund, 192-98, 1993.
11. McGlave P, Horowitz M, Weisdorf D, Shpall E. Clinical marrow transplantation. In: *Hematology*. 6(15). The Education Program of the American Society of Hematology, 152-62, 1993.
12. Shpall EJ, Stemmer SM, Bearman SI, Bast RC, Peters WP, Ross M, Jones RB. High-dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer. In: *Cancer of the Ovary*. Williams and Wilkins, 327-38, 1993.
13. Shpall EJ, Stemmer SM, Bearman SI, Jones RB. Role of autotransplantation in treatment of other solid tumors. In: *Hematology/Oncology Clinics of North America: Autologous Bone Marrow Transplantation*. 7. W.B. Saunders, 663-86, 1993.
14. Jones RB, Matthes S, Dufton C, Bearman SI, Stemmer SM, Myers SE, Shpall EJ. The pharmacology of intensive cyclophosphamide, cisplatin, and BCNU (CPA/cDDP/BCNU) in patients with breast cancer. In: *Autologous Bone Marrow Transplantation*. 6. Proceedings of the Sixth International Symposium Cancer Treatment Research Education Fund, 124-28, 1993.
15. Jacobs CA, Shpall EJ, Ball ED, Champlin RE, LeMaistre CF, Holland HK, Saral R, Berenson RJ. A prospective, randomized Phase III study using the ceprate SC stem cell concentrator to isolate CD34+ hematopoietic progenitors for autologous marrow transplantation after high dose chemotherapy. In: *Autologous Bone Marrow Transplantation*. 7. Proceedings of the Seventh International Symposium Cancer Treatment Research Education Fund, 669-78, 1994.
16. Stiff P, Shpall EJ, Tan S, Camarda M, Bayer R. High-dose combination chemotherapy and bone marrow rescue for ovarian carcinoma: Current status in the United States. In: *Autologous Bone Marrow Transplantation*. 7. Proceedings of the Seventh International Symposium Cancer Treatment Research Education, 453-58, 1994.
17. Shpall EJ, Jones RB, Bast R, Shogan J, Ross M, Edwards S, Eggleston S, Johnston C, Affronti M, Coniglio D, Peters WP. Mobilization and Collection of Peripheral Blood Progenitor Cells for Support of High-dose Cancer Therapy. In: *Bone Marrow Transplantation*. Blackwell Scientific Publications, 913-18, 1994.
18. Berenson RJ, Heimfeld S, Krieger MS, Jacobs C, Auditore-Hargreaves K, Shpall EJ. Selection and Transplantation of Autologous Hematopoietic Progenitor Cells. In: *Hematopoietic Stem Cells: Biology & Therapeutic Applications*. Marcel Dekker, Inc., 519-33, 1994.
19. Shpall EJ, Cagnoni PJ, Gehling U, Hami LS, Hogan CJ. Bone Marrow Purging. In: *High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells*, Second Edition. 15. Williams & Wilkins, 249-79, 1995.
20. Jones RB, Stemmer SM, Kasliwal R, Johnson T, Glenn S, Bunn P, Shpall EJ, Bearman SI, Ceriani R. Intensive radiolabeled anti-breast monoclonal antibody 90Y-BrE-3 with autologous hematopoietic cell support preliminary results. In: *Autologous Marrow and Blood Transplantation*. 7. Proceedings of the Seventh International Symposium Cancer Treatment Research Education Fund, 727-33, 1995.
21. Gehling UM, Hogan CJ, Gee A, Cagnoni P, Franklin W, Jones RB, Bearman SI, Ross M, Shpall EJ. Marrow Contamination: Detection and significance. In: *Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies*. Harwood Academic Publishers, 103-13, 1995.
22. Jones RJ, Cagnoni PJ, Bearman SI, Shpall EJ. Pharmacology of High-Dose Therapy with Bone Marrow Transplantation. In: *Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies*. Harwood Academic Publishers, 81-8, 1995.
23. Cagnoni PJ, Jones RB, Bearman SI, Shpall EJ. The Treatment of Ovarian Cancer. In: *Expert Consultations in Gynecologic Malignancies*. 40, 317-20, 1995.
24. Shpall EJ, Gee AP, Hogan C, Cagnoni P, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB. Bone marrow metastases. In: *Hem/Onc Clinics of North America, Haematologic Complications of Cancer*. 10(2). W.B. Saunders, 321-43, 1996.

25. Shpall EJ, Gehling U, Cagnoni PJ, Hogan C, Bearman SI, Jones RB. Sources of Hemopoietic Progenitor Cells for Transplantation. In: *Cancer Clinical Sciences in Practice: Cell Therapy*. Cambridge University Press, 113-129, 1996.
26. Nieto Y, Shpall EJ, Bearman SI, Jones RB. Ex vivo stem cell expansion. In: *Bone Marrow Transplantation*. Churchill Livingstone, 1997.
27. Shpall EJ. Peripheral blood progenitor cell graft engineering. In: *Apheresis: Principles and Practice*. AABB Press, 465-74, 1997.
28. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB. Peripheral Blood Stem Cell Harvesting and CD34-Positive Cell Selection. In: *Blood Stem Cell Transplantation*. Kluwer Academic Publishers, 143-57, 1997.
29. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Jones RB. Peripheral blood stem cells for autografting. In: *Annual Review of Medicine*. 48. Annual Reviews Inc., 241-51, 1997.
30. Roman-Unfer S, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, Shpall EJ. Autologous hematopoietic progenitor cell transplantation. In: *Cellular Support for the Oncology Pt*. Baxter Healthcare Corporation, 9-22, 1998.
31. Nieto Y, Shpall EJ, Bearman SI, Jones RB. CD34+ blood stem cell transplantation. In: *Blood Stem Cell Transplantation*. Martin Dunitz Ltd, 187-201, 1998.
32. Nieto Y, Shpall EJ, Bearman SI, Jones RB. Clinical results of autologous bone marrow transplantation for solid tumors in adults (in press). In: *Hematology: Basic Principles and Practice*. New York, 1998.
33. Shpall EJ, Warkentin PI, Jones RB. Guidelines for the procurement and manipulation of stem cells for transplantation. In: *Hematopoietic Cell Transplantation, Second Edition*. Blackwell Science, Inc., 417-20, 1998.
34. Cagnoni PJ Shpall EJ. High-dose chemotherapy for the treatment of breast cancer. In: *The Clinical Practice of Stem Cell Transplantation*. Isis Medical Media Ltd, 191-203, 1998.
35. Nieto Y, Cagnoni PJ, Shpall EJ, Bearman SI, McSweeney P, Matthes S, Holter S, Razook C, Russell P, Cook B, Yerushalmi R, Jones RB. High-dose chemotherapy in gynecologic malignancies. In: *Cancer Treatment and Research*, Boston, Kluwer Academic Publishers, 277-85, 1998.
36. Roman-Unfer S Shpall EJ. Negative and Positive Hematopoietic Cell Selection (in press). In: *High-dose cancer therapy: pharmacology, hematopoietins, stem cells*. Williams & Wilkins, 1998.
37. Jones RB, Matthes SM, Dufton C, Shpall EJ, Bearman SI, Ross M, Cagnoni P. Nitrosoureas. In: *A Clinician's Guide to Chemotherapy, Pharmacokinetics, and Pharmacodynamics*. Williams & Wilkins, 331-44, 1998.
38. Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McNiece IK. Peripheral blood stem cell transplantation. In: *Baillière's Clinical Hematology*, 1998.
39. Roman-Unfer S Shpall EJ. The use of cytokines to enhance collection of stem cells for marrow and blood transplantation (in press). In: *Clinical Applications of Cytokines and Growth Factors*. Kluwer Academic Publishers, 1998.
40. Nieto Y Shpall EJ. Autologous stem cell transplantation for solid tumors in adults. In: *Hematology/Oncology Clinics of North America*. 13(5). W.B. Saunders Company, 939-968, 1999.
41. Roman-Unfer S Shpall EJ. The use of cytokines to enhance collection of stem cells for marrow and blood transplantation. In: *Clinical Applications of Cytokines and Growth Factors*. Kluwer Academic Publishers, 369-380, 1999.
42. Roman-Unfer S, Shpall EJ, Nieto Y, Cook B. Negative and positive hematopoietic cell collection. In: *High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells*. Lippincott, William & Wilkins, 331-354, 2000.
43. Warkentin PI, Nick L, Shpall EJ. Hematopoietic Cell Procurement, Processing and Transplantation: Regulation and Accreditation (Chapter 41. In: *Thomas Hematopoietic Cell Transplantation Third Edition*, 2002.
44. Michael Murphy. Cord blood Transplantation. In: *Practical Transfusion Medicine*. Wiley, Blackwell, 453-461, 2009.
45. Warkentin, P. Shpall, E. Hematopoietic Cell Procurement, Processing, and Transplantation: Standards, Accreditation, and Regulation. In: *Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition*. 13. Blackwell Publishing, e-Book 2009.

46. Frederick Appelbaum. Hematopoietic Cell Transplantation for Breast cancer. In: Thomas' Hematopoietic Cell Transplantation. Wiley-Blackwell, 931-947, 2009.
47. Shpall Elizabeth and de Lima Marcos. Clinical Aspects of Hematopoietic Stem Cell Transplantation. In: Neoplastic Hematopathology. Ed(s) Dan Jones. Humana Press: New York, 505-511, 2010.
48. Simon Robinson, Paul Simmons, Patrick Zweidler-McKay, Elizabeth Shpall. Fucosylation for improved Engraftment. In: Cord Blood Biology Transplantation, Banking and Regulation. Ed(s) Hal E. Broxmeyer: Bethesda, Maryland, e-Book 2011.
49. McNiece, Ian, Robinson, Simon, Shpall Elizabeth. MSC for Ex Vivo Expansion of Umbilical Cord Blood Cells. In: Mesenchymal Stromal Cells. Springer Science: New York, 485-501, e-Book 2013.
50. Nieto, Yago, Shpall, Elizabeth. Autologous Hematopoietic Cell Transplantation for Breast Cancer and Germ-Cell Tumors. In: Thomas' Hematopoietic Cell Transplantation, 5th edition. Fred Appelbaum, Joseph Antin and Stephen Forman. In Press.

Books (edited and written)

N/A

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editorial Board, Cancer Research, Therapy and Control, 1991–2000

Editorial Board, Cytotherapy, 1992–2007

Editorial Board, Cytokines in Hematology/Oncology, 1993–2000

Editorial Board, Biology of Blood and Bone Marrow Transplantation, 1997–present

Editorial Board, Blood, 2004–present

Editorial Board, Treatment Strategies-Hematology, 2011–present

Member of Editorial Review Board

N/A

Journal Reviewer

Reviewer, Bone Marrow Transplantation, 1995–present

Reviewer, American Journal of Hematology, 1996–present

Reviewer, Nature Medicine, 1996–present

Reviewer, Cytotherapy, 1997–2002

Reviewer, Cancer Investigation, 1997–present

Reviewer, Cancer Research, 1997–present

Reviewer, Cell Transplantation, 1997–present

Reviewer, Clinical Cancer Research, 1997–present

Reviewer, Current Stem Cell Research, 1997–present

Reviewer, Experimental Hematology, 1997–present

Reviewer, Journal of Clinical Oncology, 1997–present

Reviewer, Journal of Immunotherapy, 1997–present

Reviewer, Leukemia, 1997–present

Reviewer, New England Journal of Medicine, 2000–present

Reviewer, PLOS One, 2012–present

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Speaker, Cord Blood Banking and Transplantation, Course Number: DoCM Grand Rounds, Course Hours: 1
First Quarter, 1/2007

Speaker, SCT/CT Program Quality Management Meeting, Course Number: MOHE0002, Course Hours: 1
10/2008

Speaker, Update on Cord Blood Transplantation, Course Number: MOHE0002, Course Hours: 1
10/2009

Speaker, DoCM Grand Rounds, Course Hours: 1
3/2010

Speaker, The Future of Cord Blood Banking and Transplantation, Course Number: MOCM002
3/2010

Speaker, Hematology Grand Rounds, Course Hours: 1
6/2010

Speaker, Pediatric Grand Rounds, Course Hours: 1
10/2010

Speaker, The Advances in Oncology Institutional Grand Rounds, Course Hours: 1
10/2010

Lecturer, Novel Allogeneic SCT Strategies in AML
10/2012

Lecturer, Novel Strategies in Stem Cell Transplantation, Course Hours: 0
10/2012

Speaker, The Division of Cancer Medicine Grand Rounds, The University of MD Anderson Cancer Center, Course Hours: 1
6/2013

Speaker, The Division of Cancer Medicine Grand Rounds, Course Hours: 1
11/2013

Supervisory Teaching Committees

Advisory Committees

Research Mentor, Thesis Advisory Committee, University of Texas Health Sciences Center and MD Anderson Experimental Pediatrics in Laurence Cooper's laboratory, Denise Kellar, PhD, 2008–2009

Research Mentor, Thesis Advisory Committee, Baylor College of Medicine in Catherine Bollard's Laboratory, Sharon Lam, PhD, 2010–2011

Research Mentor, Thesis Advisory Committee, MD Anderson Graduate School of Biologic Sciences and Experimental Pediatrics in Laurence Cooper's laboratory, Radhika Thokala, PhD, 2010–present

Research Mentor, Thesis Scholarship Oversight Committee, Baylor College of Medicine in Catherine Bollard's Laboratory, Paul Castillo, PhD, 2012–present

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

Research Mentor, Attend conferences and lectures, Sister Institution Associate, Kim Darae, Contact Hours: 8 hours, 2/2009–3/2009

Mentor, Nelli Bejanyan, 10/2011

Graduate Students

N/A

Postdoctoral Research Fellows

Laboratory Investigator, Xiaoyin Liu, PhD, 10/2001–present

Laboratory Investigator, Hong Yang, Ph.D., 4/2003–present

Laboratory Investigator, Simon Robinson, Ph.D., 9/2003–7/2013

Laboratory Investigator, Dongxia Xing, Ph.D., 10/2003–5/2012

Laboratory Investigator, William Decker, Ph.D., 4/2004–5/2011

Laboratory Investigator, David Steiner, Ph.D., 6/2005–12/2008

Research Mentor, The University of Texas M.D. Anderson Cancer, Beatriz Martin Antonio, Ph.D., 2/2012–12/2013

Research Mentor, Piyanuch Kongtim, 2/2012–present

Laboratory Investigator, Zakaria M Grada, Ph.D., 8/2012–6/2013

Clinical Residents and Fellows

Hematology-Oncology Fellowship Rotation, Fellowship Rotation, University of Colorado Health Sciences Center, Malcom Purdy, M.D., 5/1993–5/1994

BMT Fellowship Laboratory Rotation, Fellowship Rotation, University of Colorado Health Sciences Center, Susan Meyers, M.D., 5/1994–5/1995

BMT Fellowship Laboratory Rotation, Fellowship Laboratory Rotation, University of Colorado Health Sciences Center, Susan Roman-Unfer, M.D., 5/1994–5/1995

BMT Fellowship Laboratory Rotation, Fellowship Rotation, University of Colorado Health Sciences Center, Ursula Gehling, M.D., 5/1994–5/1995

BMT Fellowship Laboratory Rotation, BMT Fellowship Rotation, University of Colorado Health Sciences Center, Ronit Yerushalmit, M.D., 5/1999–5/2000

SCTCT Fellowship Laboratory Rotation, Fellowship Rotation, Niu Ting, M.D., 5/2004–5/2005

BMT Fellowship Laboratory Rotation, Simrit Parmar, M.D., 5/2004–5/2005

Hematology-Oncology Fellowship Laboratory Rotation, Fellowship Rotation, Alyssa Rieber, M.D., 5/2005–5/2006

SCTCT Fellowship Laboratory Rotation, Fellowship Rotation, Nina Shah, M.D., 5/2007–5/2010

Other Supervisory Teaching

Student, Silva Cody Cayetano, High school student, 6/2008–8/2008

Mentor, The University of Texas M.D. Anderson Cancer Center, Zartash Gul, 2/2012–5/2012

Mentor, Farzal Anwar, 10/2013–11/2013

Teaching Outside of Current Institution

Formal Teaching

Courses Taught

N/A

Training Programs

N/A

Other Formal Teaching

Lecturer, Cord Blood Banking and Transplantation, The University of Texas Medical Branch
4/2012

Speaker, Immunotherapy in CLL- Truly Exciting at Last, Westin Galleria Hotel, Course Hours: 0
9/2013

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

SCTCT Fellowship Laboratory Rotation, Chair, GSBS Ph.D. Program, UTHSCH, Denise L. Kellar, 11/2008–11/2009

Clinical Residents and Fellows

N/A

Other Supervisory Teaching

Co-Chair, 2012 ASBMT Clinical Research Training Course, Hotel Park City, Scholars and Faculty, ASBMT Training Course, 7/2012

Chair, 2013 ASBMT Clinical Research Course, La Posada de Santa Fe, Scholars and Faculty, 2013 ASBMT Clinical Research Course, 7/2013

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

EHA Executive Board, ESH-EHA Scientific Workshop on Mesenchymal Stem Cell, Mandelieu, France, Co-Organizer, 6/2008

International Society for Cellular Therapy's Executive Board (ISCT), 9th Annual Somastic Cell Therapy Symposium, Bethesda, MD, Chair, 9/2009

The Medal Group, LLC, First International Hematologic Malignancies Conference "Bridging the Gap:2010," Singapore, Singapore, Chair, 2/2010

The Medal Group, LLC, 2nd, International Hematologic Malignancies: Bridging the Gap 2011, Singapore, Singapore, Chair, 3/2011

1st Annual Update on Breakthroughs in Hematology, The Medal Group Corporation, Bangkok, Thailand, Chair, 9/2011

European Hematology Association, ESH-EHA Scientific Workshop on Anti-inflammatory & Immune Modulatory Agents, Cannes Mandelieu, France, Chair, 4/2012

2012 ASBMT Clinical Research Training Course, American Society for Blood & Marrow Transplantation (ASBMT), Park City, UT, Co-Chair, 7/2012

International Society for Cellular Therapy (ISCT), 19th, Annual Meeting of International Society for Cellular Therapy, Auckland, New Zealand, Chair, 4/2013

2013 ASBMT Clinical Research Training Course, American Society for Blood & Marrow Transplantation (ASBMT), Santa Fe, NM, Chair, 7/2013

Presentations at National or International Conferences

Invited

The Ex Vivo Expansion of Cord Blood for the Clinic", Eurocord Meeting on Stem Cell Transplantation – Annency, Annency, France, 1/1/1999

Bone Marrow Transplantation for Solid Tumors Other than Breast Cancer, Tandem Meetings of the International Bone Marrow Transplant Registry/American Society of Blood and Marrow Transplantation, Keystone, CO, 2/1/1999

Dendritic Cell Vaccines in the Post-Transplant Setting, Southwest Oncology Group Meeting, Phoenix, AZ, 4/1/1999

Future Directions in Hematopoietic Cell Therapy for Breast Cancer Patients, Dana Farber Cancer Center Medical Grand Rounds, Boston, MA, 4/1/1999

A Randomized Trial of Stem Cell Purging for Breast Cancer Patients with Stage II/III, 10+ Node Disease, American Society of Clinical Oncology Breast Cancer Intergroup Meeting, Atlanta, GA, 5/1/1999

Preservation and Transplantation of Fetal Cord Blood, University of Colorado Immunology Department Symposium, Keystone, CO, 5/1/1999

The Status of Breast Cancer Treatment and Transplantation, Blue Cross Blue Shield Policy Forum, Los Angeles, CA, 6/1/1999

University of Colorado Cord Blood Banking and Transplant Experience, Netcord International Meeting on Cord Blood Banking and Transplantation, Dusseldorf, Germany, 8/1/1999

High-Dose Therapy for Breast Cancer Patients, American Cancer Society, San Diego, CA, 1/1/2000

High-Dose Therapy for Breast Cancer, Scripps Clinic Symposium on Cancer Therapy, La Jolla, CA, 2/1/2000

Stem Cell Processing, Expansion and Selection, Tandem Meetings of the International Bone Marrow Transplant Registry/American Society of Blood and Marrow Transplantation, Anaheim, CA, 3/1/2000

Breast Cancer: Who should go to transplant, Annual Meeting of the Canadian Bone Marrow Transplant Group, Quebec, Canada, 4/1/2000

The University of Colorado Experience with Expanded Cord Blood", Tokyo 5th International Symposium of Cord Blood Transplantation, Tokyo, Japan, 6/22/2000

The Ex Vivo Expansion of Cord Blood, Eurocord International Symposium on Stem Cell Transplantation, Paris, France, 6/30/2000

Cord Blood Transplantation, 13th, International Symposium on Treatment of Leukemia and Cancer, New York, NY, 7/16/2000

Cord Blood Transplantation" and "Transplants for Non-Hodgkin's Lymphoma, South American Symposium on Bone Marrow Transplantation, Curitiba, Brazil, 7/20/2000

High-Dose Therapy for Breast Cancer Patients, The Stanford University 7th, Biennial National Symposium on Hematopoietic Cell Transplantation, Palo Alto, CA, 9/1/2000

Cord Blood Banking – Collection Facilities, Netcord-New York Blood Center Seminar on Cord Bank Inspections, New York, NY, 11/10/2000

Cord Blood Transplantation, Forum on Canadian National Policy for Stem Cell Transplantation, Ottawa, Canada, 11/16/2000

Transplantation of Adult and Pediatric Cancer Patients with Cord Blood Progenitors Expanded Ex Vivo, 42nd, Annual Meeting of the American Society of Hematology, Orlando, FL, 12/1/2000

History and Current Status of the Foundation for the Accreditation of Hematopoietic Cell Therapy, BMT Tandem Meeting, Orlando, FL, 2/1/2001

Current Status and Future Directions of the University of Colorado Cord Blood Bank, Netcord Meeting, New York, NY, 3/1/2001

University of Colorado Cord Blood Transplant Studies, StemCyte Advisory Committee Meeting, San Francisco, CA, 5/1/2001

Cord Blood Transplantation, Annual Meeting of the International Society of Hematotherapy and Graft Engineering (ISHAGE), Quebec City, 6/1/2001

Cord Blood Banking – Collection Facilities, Annual Meeting of the International Society of Hematotherapy and Graft Engineering (ISHAGE), San Diego, CA, 6/14/2001

Cord Blood Banking and Transplantation in the United States, International Symposium on Stem Cells: Biotechnology, and Clinical Applications, Twain, China, 9/1/2001

Latest Data In Cord Blood Transplantation, Meeting of the Northern Colorado Cancer Group, Ft. Collins, CO, 9/1/2001

Cord Blood Banking and Ex Vivo Expansion, Israeli Symposium on Tissue Banking (EABT) – Eilat, Israel, 10/1/2001

The Clinical Use of Expanded Cord Blood Progenitors, 5th International Symposium on In Utero Stem Cell Transplantation and Gene Therapy, Reno, NV, 10/1/2001

The Future of Dendritic Cell Therapy, COBE-Gambro Laboratories Seminar on Dendritic Cell Therapy, Lakewood, CO, 3/1/2002

Cord Blood Transplantation, MD Anderson Blood and Marrow Transplantation Faculty Conference, Houston, TX, 4/14/2002

Dendritic Cell Therapy for Breast Cancer Patients, Miltenyi Dendritic Cell Meeting, Denver, CO, 4/30/2002

Evaluation of Clinical Transplant Facilities, Seminar on Joint Accreditation Committee of ISCT and EBMT, Barcelona, Spain, 5/1/2002

The Ex Vivo Expansion of Cord Blood, International Society of Cell Therapy (ISCT), Barcelona, Spain, 5/1/2002

Cord Blood Expansion Experience, Gamida Cell Meeting on Cord Blood Expansion, The University of Colorado, Washington, DC, 6/2002

High-Dose Therapy for Breast Cancer Patients, The Stanford University 8th Biennial National Symposium on Hematopoietic Cell Transplantation, Palo Alto, CA, 9/1/2002

University of Utah Symposium on Stem Cell Transplantation Cord Blood Transplantation and Expansion, 10/1/2002

Clinical Development of StemEx, Status of Phase I Study, American Society of Hematology, 44th Annual Meeting and Exposition, Philadelphia, PA, 12/1/2002

Tandem BMT Meeting, Keystone, CO, 1/1/2003

Umbilical Cord Transplant Symposium, International Conference, Duarte, CA, 4/1/2003

Stanford University 8th Biennial National Symposium on Hematopoietic Cell Transplantation, Palo Alto, CA, 9/1/2003

Celtrans Advisory Board Meeting, Missoula, MT, 9/1/2003

FACT University of Nebraska Medical Center, 11/1/2003

ASH Conference, San Diego, CA, 12/1/2003

BMT Tandem Meeting, Orlando, FL, 2/1/2004

EBMT Conference, Barcelona, Spain, 3/1/2004

Texas Transplant Institute, San Antonio, TX, 4/1/2004

Cord Blood Transplantation, 2nd, Annual Intl Umbilical Cord Blood Transplantation Symposium, Los Angeles, CA, 5/1/2004

Cord Blood Transplantation, 8th, Tokyo Intl Symposium on Cord Blood Transplantation, Tokyo, Japan, Japan, 7/1/2004

Represented MDACC at Texas Legislature re: Stem Cell Bills, Austin, TX, 4/1/2005

Canadian Hematology Society, 6/1/2005

Board Review in Hematology and Medical Oncology, 9/1/2005

Cord Blood Transplantation and Graft Engineering, International Society of Cell Therapy, ISCT, Miami, FL, 5/2008

MSC and Cord Blood expansion, International ESH-EHA Scientific Workshop Biology and Clinical Applications of Mesenchymal Stem Cells, Sofitel Mandelieu La Napoule, France, Paris De Gaulle, France, France, 6/2008

Current Status of Umbilical Cord Blood Transplantation: Biology, Banking and Clinical Practice, AABB Annual Meeting & TXPO 2008, Convention of Palais De Congres De Montreal, Montreal, Canada, 10/7/2008

The Future of Cord Blood Transplantation, Annual International conference Sheba, Sheba Medical Center scientific meeting on translational research of cancer, Israel, Tel viv, Israel, 1/9/2009

Cord Blood Banking and Transplantation Current Status and Future Directions, Annual BMT Tandem Meeting, BMT, Tampa, FL, 2/11/2009

Mesenchymal Stem Cell Based Cord Expansion Trail Cell Working Group at EBMT, EBMT 35 Annual Meeting of the European Group for Blood & Marrow Transplantation, EBMT, Goteborg, Sweden, 3/26/2009

Improving Outcomes in Cord Blood Transplant: Research & Practice, 22nd Annual Council Meeting, The National Marrow Donor Program, Minneapolis, MN, 11/6/2009

Cord Blood Stem Cell Expansion, 51st ASH Annual Meeting and Exposition, The American Society of Hematology, New Orleans, LA, 12/29/2009

Role of Transplant in CLL, First International Hematologic Malignancies Conference" Bridging the Gap 2010," The Medal Group, LLC, singapore, Singapore, Singapore, 2/6/2010

Overcoming Challenges in Cord Blood Transplant and Cord Blood Banking, National University Cancer Institute, The Medal Group, LLC, Singapore, Singapore, Singapore, 2/7/2010

Cord Blood Transplantation, China Medical University Hospital, Taipei, Taiwan, 2/9/2010

Graft Failure and Engraftment in Cord Blood Transplantation, BMT Tandem Meeting, ASBMT/CIBMTR, Orlando, FL, 2/27/2010

Cord Blood Banking, First International Conference on Hemaopoietic Stem Cell Transplantation Focus on Alternative Donors, Hospital-Instituto Sirio-Libanés De Ensino E Pesquisa, Sao Paulo, Brazil, 3/12/2010

In Vitro Cord Blood HSC Expansion, First International conference on Hematopoietic Stem Cell Transplantation Focus on Alternative Donors, Hospital Instituto-Sirio-Libanés De Ensino E Pesquisa, Sao Paulo, Brazil, 3/12/2010

Overview of Cell and BioBanking, and Good Manufacturing Practice (GMP), 14th Congress of EHA & American Society of Hematology, The Translational Research Training in Hematology, Barcelona, Spain, 3/20/2010

Transplantation Dreaming, 15th Congress of EHA, European Alliance for Therapy of CLL, American Society of Hematology, Barcelona, Spain, Spain, 7/14/2010

Current Chemotherapy Protocols and Their Impact on Invasive Fungal Infections, The Medal Group Corporation, The Second International Hematologic Malignancy Conference " Bridging the Gap: 2011," Singapore, Singapore, 3/19/2011

Updated Results on Cord Blood vs MUD Transplant, The Medal Group Corporation, The Second International Hematologic Malignancy Conference " Bridging the Gap: 2011," Singapore, Singapore, 3/20/2011

Mesenchymal Stem Cell Based Cord Blood Expansion Leads to Rapid Engraftment of Platelets, Cord Blood Forum, Inc, 9th Annual International Umbilical Cord Blood Transplantation Symposium, San Francisco, CA, 7/25/2011

Reduced Intensity Conditioning Transplant in AML and role of post-transplant maintenance therapy, The Medal Group Corporation, 1st Annual Update on Breakthroughs in Hematology, Bangkok, Thailand, 9/2/2011

Challenges in Stem Cell Mobilization, 1st Annual Update on Breakthroughs in Hematology, The Medal Group Corporation, Bangkok, Thailand, 9/3/2011

Ex Vivo Expansion of CB Cells: Is still a possible option, ESH European School of Haematology, World Cord Blood Congress III, Rome, Italy, 10/27/2011

Anti-leukemia NK cells, ESH European School of Haematology, ESH European School of Haematology and EBMT, Rome, Italy, 10/28/2011

Clinical Cellular Therapy, BMT Tandem meeting, BMT Tandem Scientific Meeting, San Diego, CA, 2/3/2012

Cord Blood Transplantation, 38th Annual Meeting of the European Group for Blood and Marrow Transplantation, European Group for Blood and Marrow (EBMT), Geneva, Switzerland, 4/2/2012

Expansion of Cord Blood-derived Stem Cells in Co-cultures with MSCs, ESH-EHA Scientific Workshop on Anti-Inflammatory & Immune Modulatory properties of MSCs, European Hematology Association, Cannes Mandelieu, France, 4/22/2012

The Future of Cord Blood Transplantation, 18th ISCT Annual Meeting, International Society for Cellular Therapy (ISCT), Seattle, WA, 6/6/2012

Virus and Tumor Specific Cord Blood- Derived T Cells for Patients after Cord Blood Transplantation, 10th Annual Intl Cord Blood Symposium, Cord Blood Transplantation, San Francisco, CA, 6/9/2012

Cord Blood Expansion, Nobel conference Hematopoietic Stem Cells: From Basic Science to Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden, 6/20/2012

Ex-Vivo Expansion Technology to improve engraftment and reduce graft failure rate, World Cord Blood Congress, World Cord Blood Congress, Boston, MA, 9/19/2012

Novel Approaches Using MSC's, 19th ISCT Annual Meeting, International Society for Cellular Therapy (ISCT), Auckland, New Zealand, 4/23/2013

NK Cellular Therapy for CLL, iWCII Scientific Board and Programme Committee, Fifteenth International Workshop on Chronic Lymphocytic Leukaemia, Cologne, Germany, 9/10/2013

Cord Blood Banking, ESH European School of Haematology, World Cord Blood Congress IV, Monaco, 10/24/2013

Other, Including Scientific Exhibitions

Cord Blood Expansion Experience, Gamida Cell meeting The University of Colorado Cord Blood Expansion, The University of Colorado, Washington, DC, 6/1/2002

Umbilical Cord Blood, 3rd, Annual Intl Umbilical Cord Blood Transplantation Symposium, Los Angeles, CA, 7/2005

Cord Blood Transplantation, 4th, Annual Singapore Society of Hematology, Singapore, Terrain, 3/2006

Cellular Therapy Workshop, ISCT Conference, Berlin, Germany, 5/2006

The role of fetal cord blood in the African American Population, Annual Convention & Scientific Assembly for National Medical Association, Dallas, TX, 8/2006

Cord Blood Future Directions, International Society of Cell Therapy (ISCT) Six annual Somatic Therapy Symposium, Bethesda, MD, 9/2006

Cord Blood Mesenchymal Stem Cells Co-Cultures, Biology and Clinical Applications of Mesenchymal Stem Cells, International workshop, Mandelieu La Napoule, France, France, 10/2006

Cord Blood Expansion with Mesenchymal Stem Cells, 5th, International Umbilical Cord Blood Transplantation Symposium, Los Angeles, CA, 5/2007

The Mesenchymal Cells, Biology and Clinical Applications of Cord Blood Cells, International workshop, Maison De la Chimie, Paris, France, France, 10/19/2007

Overview of Stem Cell Therapy Cord Blood Therapy, RSNA, McCormick Place Lakeside Learning Center, Chicago, IL, 2/28/2008

Cord Blood Physician's Conference to Establish Guidelines for Optimal Conduct of Cord Blood, NMDP, National Marrow Donor Program, Minneapolis, MN, 8/7/2013

Hematopoietic Stem Cell Transplantation for AML, 55th ASH Annual Meeting and Exposition, American Society of Hematology (ASH), New Orleans, LA, 12/6/2013

Seminar Invitations from Other Institutions

Future Directions in Hematopoietic Cell Therapy for Breast Cancer Patients, Medical Grand Rounds, Dana Farber Cancer Center, Boston, MA, 4/1999

High-Dose Therapy for Breast Cancer, Scripps Clinic Symposium on Cancer Therapy, La Jolla, CA, 2/2000

High-Dose Therapy for Breast Cancer Patients, 7th Biennial National Symposium on Hematopoietic Cell Transplantation, The Stanford University Palo Alto, Los Angeles, CA, 9/2000

Cord Blood Banking Collection Facilities, -New York Blood Center Seminar on Cord Bank Inspections, New York, NY, 11/2000

High-Dose Therapy for Breast Cancer Patients, 8th Biennial National Symposium on Hematopoietic Cell Transplantation, The Stanford University, Palo Alto, CA, 9/2002

Cord Blood Transplantation, Texas Transplant Institute, San Antonio, 4/2004

Cord Blood Transplantation and Expansion, Grand Round, University of Utah, Salt Lake City, UT, 2/2006

Cord Blood Expansion, Fred Hutchison Cancer Center Grand Rounds, Seattle, WA, 10/2006

Cord Blood Transplant Grant, NIH/NCI, Washington, DC, 4/2008

Roundtable on Clinical Endpoints for Phase III Trials in Acute GVHD, Osiris Therapeutics, Osiris Therapeutics, Baltimore, MD, 5/2008

Future of Cord Blood Transplantation, University of Miami Miller School of Medicine Grand Rounds, Miami, FL, 3/11/2009

Umbilical Cord Blood Banking and Transplantation, The Vintage Club in Indian Wells, California, Indian Wells, CA, 3/23/2009

Advances in Umbilical Cord Blood Transplantation, Eric Feldman Hematology Oncology at Weill Cornell Medical College, New York, NY, 7/23/2010

Umbilical cord blood cell expansion platforms, Cell-based therapies: a new era in patient care, Nationwide Children's Hospital, Columbus, OH, 10/14/2013

Lectureships and Visiting Professorships

ASBMT Corporate Council Meeting, ASBMT Corporate Council, Phoenix, AZ, 10/3/2011

The Future of Cord Blood Cell Therapy, Stem Cell Institute University, Minneapolis, MN, 11/20/2013

Other Presentations at State and Local Conferences

FACT Inspection, Children's Memorial Stem Cell Program, Children's Memorial, Chicago, IL, 9/10/1997

FACT Inspection, Fox Chase Cancer Center, Philadelphia, PA, 5/28/1998

FACT Inspection, University Medical Center, Texas Tech University Health Sciences, Lubbock, TX, 8/19/1998

FACT Inspection, Stanford University Medical Center, Stanford, Los Angeles, CA, 10/15/1998

FACT Inspection, NOVA Fairfax Hospital, Fairfax, VA, 2/10/2000

FACT Inspection, Seattle Cancer Care Alliance, Seattle, WA, 8/26/2003

Celtrans Advisory Board Meeting, Missoula, MT, 9/2003

Consultant for Transplant Trials, Medical College of Wisconsin, Wisconsin, 4/2004

FACT Inspection, Besancon Cord Blood Bank, Besancon, France, 6/29/2004

Stem Cell Bills, Represented MD Anderson Cancer Center at Texas Legislature, Austin, TX, 4/2005

FACT Inspection, Carolinas, Cord Blood Bank at Duke, Durham, NC, 8/17/2005

Cord Expansion Study, Amgen- Gamida Cell Meeting, Thousand Oaks, CA, 12/2005

Cellerant Advisory Board, San Francisco, CA, 3/2006

Netcord Strategic Planning Retreat, Düsseldorf, Germany, 6/2006

StemEx Pivotal Study Investigator Meeting, Newark, NJ, 10/2006

FACT Inspection, Cord Blood Bank at Eurocord Nederland Foundation, Leiden, Netherlands, 3/22/2007

Netcord- Executive Committee meeting, Lyon convention Centre, Lyon, France, 3/24/2007

Testified at FDA re: Proposed Cord Blood Licensing regulations, Netcord- NMPD Standards Committee Meeting, Washington, DC, 3/28/2007

Stem Cell Bills, Represented MD Anderson Cancer Center at Texas Legislature, Governmental Relations M.D. Anderson Cancer Center, Austin, TX, 4/12/2007

GVHD scientific advisory board meeting, Osiris, Baltimore, MD, 9/11/2007

stem cell transplantations and immune reconstitution, CLLGlobal Research Foundation/U.S./European Alliance for Treatment of CLL, London, United Kingdom, 9/17/2007

NMDP Cord Blood Committee Meeting, Netcord- NMPD Cord blood Committee Meeting, National Marrow Donor Program, Minneapolis, MN, 10/5/2007

FACT Inspection, Cord Blood Bank at Duke University Medical Center, Duker University, Durham, NC, 11/8/2007

Cord Blood Demonstration Project, HRSA and NMDP, Washington, DC, 12/6/2007

CBR Overview/Outline of related Donation Structure, Cord Blood Registry, Cord Blood Recruitment Center for Cord blood, Cord blood Recruitment, Tucson, AZ, 2/2008

FACT Inspection, Cord Blood Bank at the Manchester Grand Hyatt, Tandem Meeting, BMT Tandem, San Diego, CA, 2/17/2008

Cord Blood Registry, HRSA, Tucson, AZ, 2/29/2008

Netcord Board of Directors, Board of Directors at EBMT, EBMT, Florence, Italy, 3/28/2008

Advisory Council Blood Stem Cell Meeting, HRSA and ASBMT, Reagan, DC, Reagan, 4/2008

Cord blood PO1, NIH, Bethesda, MD, 4/2008

Stem Cell Bills, Represented at MD Anderson Cancer Center, MD Anderson Cancer Center, Governmental Relations, Austin, TX, 5/2008

HRSA and NMDP, Viacord Processing Lab Visit Meeting, NMDP, Cincinnati, OH, 7/25/2008

Texas Vaccine Center Meeting, Baylor University, Dallas, TX, 8/22/2008

FACT Inspection, Cord Blood Bank Standards, New York Hospital, New York, NY, 9/22/2008

FACT Inspection, Sheba Cord Blood Bank, Tel Aviv, Israel, 7/27/2009

Netcord Strategic Planning Retreat, International NetCord Foundation, Barcelona, Spain, 9/4/2009

NMDP Network Engagement Workshop, NMDP, Chicago, IL, 10/7/2009

Joint Optimal Donors and GVHD SOSS Committee meeting, Randomized cord expansion trial, Joint Optimal Donors, Arlington, VA, 10/12/2009

NMPD Cord blood Committee Meeting, NMDP, The depot location, Minneapolis, MS, 11/19/2009

Netcord-NMPD Cord Blood Advisory Group Meeting, Netcord-NMPD, San Francisco, CA, 6/2/2010

CLLGRP Advisory Board Meeting, Celgene, Barcelona, Spain, 6/12/2010

FDA Project with Phase II study of Cord Blood expansion, Angioblast, Rockville, MD, 7/28/2010

Council CBU Engraftment Session, NMDP, Minneapolis, MN, 10/16/2010

Cord Blood Bank Site Visit, HRSA, New York, NY, 10/21/2010

NMDP Cord Blood Advisory Group Meeting, NMDP, Minneapolis, MN, 10/23/2010

Cord Blood Stem Cell Expansion, 52th, ASH Annual Meeting and Exposition, The American Society of Hematology, Orlando, FL, 12/6/2010

FACT Cord Blood Inspection and Accreditation Workshop, International Umbilical Cord Blood Transplantation Symposium, FACT Foundation For The Accreditation of Cellular Therapy, Omaha, NE, 7/26/2011

Enhance Engraftment, Hospira, Inc, Hospira Regenerative Medicine Scientific Advisory Panel, Chicago, IL, 8/16/2011

Expand Donor Population, Hospira, Inc, Hospira Regenerative Medicine Scientific Advisory Panel, Chicago, IL, 8/21/2011

Cord Blood Banking and Transplantation, Viacord, Houston Gynecological & Obstetrical Society, Houston, TX, 9/8/2011

ASBMT and NMDP Meeting, America Society for Blood and Marrow Transplantation, ASBMT Board and SCI Symposia, Minneapolis, MN, 9/13/2011

Targeting Risk for Graft Versus Host Disease, Advisory Panel Meeting, Athersys, BMT Tandem Meeting, San Diego, CA, 2/2/2012

Perspectives on Cord Blood Biology and Clinical Applications, Second Howard P. Milstein Symposium, New York Blood Center, Inc, New York Blood Center, New York, NY, 4/10/2012

BMT Field and Society Strategic Plans, Celgene and Sanofi Aventis, Pharma Meeting, New Jersey, NY, 5/3/2012

ASBMT/CIBMTR/NMDP Leadership Meeting, America Society for Blood and Marrow Transplantation, ASBMT, Minneapolis, MN, 9/5/2012

Novel Allogeneic SCT Strategies in AML, SOHO 2012 Annual Meeting, The University of MD Anderson Cancer Center, The University of MD Anderson Cancer Center (Hamatologic Malignancies 2012), Leukemia, Houston, TX, 10/12/2012

Novel Strategies in Stem Cell Transplantation, The University of MD Anderson Cancer Center, The University of MD Anderson Cancer Center, Medical Oncology and Hematoogy 2012, Houston, TX, 10/20/2012

Cellular Immunotherapy: ready for prime time?, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center (GAP 2013 Conference), Global Academic Programs, Houston, TX, 4/3/2013

FACT Strategic Planning Retreat, Foundation for the Accreditation of Cellular Therapy, FACT Board of Directors, Chicago, IL, 5/7/2013

4 HRSA Cord Blood Strategy Meeting, National Marrow Donor Program (NMDP), HRSA, DC, WA, 9/4/2013

ASBMT Strategic Planning Retreat, American Society for Blood and Marrow Transplantation, Strategic Planning Retreat & Board of Directors Meeting, Chicago, IL, 9/18/2013

Immunotherapy in CLL- Studies, SOHO 2013 Annual Meeting, The University of MD Anderson Cancer Center, The University of MD Anderson Cancer Center (Hamatologic Malignancies 2012), Leukemia, Houston, TX, 9/18/2013

FACT Inspection, FACT-Jackie International Cellular Therapy Standards, Foundation for the Accreditation of Cellular Therapy, Seattle Cancer Care Alliance, Seattle, WA, 11/6/2013

HPDSC Advisory Board Meeting, Celgene Cellular Therapeutics Advisory Board, Celgene Corporation, Newark, NJ, 11/18/2013

SCT Program and Plans for allogeneic transplants, Banner Health, Phoenix, AZ, 12/22/2014

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American College of Physicians

Associate Member, 2/1984–12/2000

American Society Clinical Oncology

Associate Member, 3/1986–11/2000

American Association Cancer Research, Houston, TX

American Association Cancer Research, 1/1988–12/1991

American Society Clinical Oncology

Member, 1/1988–12/1997

AACR, TX

Member, 1/1990–12/1997

Southwest Oncology Group

Co-Chairman, 2/1991–12/2000

American Society of Hematology

Member, 1/1992–present

International Association for Breast Cancer Research

Member, 1/1992–12/2000

International Society for Cellular Therapy

Member, 1/1992–present

Women in Cancer Research

Member, 1/1992–12/2000

North American Autologous Bone Marrow Transplant Registry Audit Committee

Chairman, 1/1994–12/1997

American Society Clinical Oncology Public Relations Committee

Member, 4/1994–12/1995

American Society for Blood and Marrow Transplantation Accreditation Committee

Chairman, 1/1995–12/2001

American Society of Breast Disease
Member, 1/1995–12/2002

Foundation Accreditation of Hematopoietic Cell Therapy
Board Member, 2/1995–present

American Society Clinical Oncology Education Committee
member, 3/1995–present

(Founding), Foundation Accreditation of Hematopoietic Cell Therapy
President, 4/1995–12/2003

Netcord
Board Member, 1/1997–present

FACT -Netcord Cord Blood Standards Committee
Chairman, 1/1999–present

Netcord
Vice President, 1/2006–present

National Marrow Donor Program Standards Committee
Member, 5/2006–present

US/European Alliance for the Treatment of CLL-Stem Cell Transplantation and Immune
Reconstitution Working Group
Member, 7/2007–present

Fact Collection Standards Committee, Houston
Member, 11/2007–present

Clinical Trials Network Committee on Gene and Cell Therapy
Member, 1/2009–present

ASCO, Houston, TX
Member, 6/2009–present

AACR, TX
Member, 7/2009–present

American Society of Blood and Transplantation (ASBMT)
Vice President, 12/2010–12/2011

CIBMTR Advisory Committee
Member, 3/2011–3/2013

Executive Committee,
Member, 3/2011–3/2013

American Society of Blood and Transplantation
President Elect, 12/2011–12/2012

American Society of Blood and Transplantation
President, 12/2012–12/2013

AnorMED Advisory Board

International Society for Hematotherapy and Graft Engineering

Search Committee for General Internal Medicine

Local/State

Harris County Medical Society -HCMS, Houston, TX
Member, 1/2008–present

UNIQUE ACTIVITIES

N/A

DATE OF LAST CV UPDATE

2/19/2014